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CHAPTER 1 
Background and aims of the study 
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Background 
Extracorporeal shock wave lithotripsy (ESWL) of gallbladder stones was clinically introduced 
in 1985 [I]. Before that, cholecystectomy had been the unchallenged standard therapy for 
symptomatic gallbladder stones for over a century [2]. 
Expectations with regard to ESWL ran rather high after publication of the first results in a 
large series of patients [3]. This actuarial analysis of 175 patients indicated that not less than 
91 % of the patients rendered stone free at a negligible complication rate. Lay press 
interpreted these data as if surgery would soon become obsolete for the majority of gallstone 
patients, an interpretation also heard from optimistic physicians at scientific meetings. As a 
consequence of this optimism, an unbridled purchase of gallstone lithotriptors occured by 
hospitals all over Gerntany, the country of origin ofESWL. This optimism seemed justified 
because a decade earlier, ESWL revolutionized urological practice. Shortly after the 
introduction of ESWL, surgery for urinary tract stones became restricted to less than 5 % of 
the patients [4]. 
The professional attitude in The Netherlands, however, was reserved. Valid studies on the 
efficacy, safety and cost-effectiveness were requested before ESWL were to be accepted as 
a serious treatment modality for symptomatic gallstones [5,6]. This inspired our group to 
start with in vitro and in vivo studies. The whole project was named the Rotterdam Gallstone 
Study, or ROGAL Study. This ROGAL Study also included a randomized clinical trial and 
a cost-effectiveness analysis. 
Major considerations to perform a prospective randomized study were twofold. First, such 
a trial was considered essential, because all the then available reports on gallstone lithotripsy 
were not controlled [7]. And second, because ESWL of urological stones had replaced 
surgery almost completely despite that a randomized trial was never performed. This had 
always been a major point of criticism [8]. 
A cost-effectiveness analysis was initiated for two reasons. First, because of the apparent 
medical and economical impact of gallbladder stones disease: 10% of the adult population 
have gallstones [9,10] and approximately 14,000 cholecystectomies are performed in The 
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Netherlands each year [11]. This accounts for 180 million of yearly expenses [11] and an 
economic evaluation of the consequences of ESWL was, obviously, mandatory. Second, 
because of the fact that reports on whether ESWL would lead to reduced costs were 
speculative and contradictory [12,13]. Moreover, the results of a cost-effectiveness analysis 
would provide information on the general need for lithotriptors in The Netherlands. 
The experimental and first clinical results of the ROGAL Study have already been published 
[14,15]. The results of the randomized study are presented in this thesis. 
Aims of the study 
Aims of this study were to investigate the particular role of ESWL in the whole spectrum of 
treatment modalities for symptomatic gallstones. ESWL's potential value was investigated 
in separate studies. These studies evaluated ESWL in terms of eligibilty, stone clearance, 
safety, symptom relief, general well being and cost-effectiveness. 
During the performance of the ROGAL Study, it became evident that the public's interest 
in the randomized part of the study was relatively poor. Because this hampered patient 
accrual, the factors influencing this phenomenon were investigated. One of the major 
determinants of the. loss of interest in ESWL was the introduction of laparoscopic 
cholecystectomy [16]. This new technique was also evaluated by means of the same 
questionnaires as used for the evaluation of ESWL. Finally, the potential value of 
extracorporeaJ shock waves in fields other than gallbladder stones was studied. 
The following questions were discussed in this thesis: 
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what are the currently available treatment modalities for symptomatic gallstones? 
(Chapter 2) 
how many patients are eligible for ESWL? (Chapter 3) 
what is the efficacy and safety of ESWL in a large group of patients? (Chapter 4) 
what is the course of biliary and gastrointestinal symptoms after ESWL in comparison 
with conventional cholecystectomy, the gold standard? (Chapter 5) 
how is the quality of life after ESWL in comparison with conventional 
cholecystectomy? (Chapter 6) 
what is the cost-effectiveness of ESWL? (Chapter 7) 
what implications have the findings at oral cholecystography for nonsurgical treatment 
modalities for symptomatic gallstones? (Chapter 8) 
what factors resulted in a relatively poor patient accrual into the randomized part of 
the study 'ESWL versus Cholecystectomy'? (Chapter 9) 
what is the course of biliary and gastrointestinal symptoms and qualtity of life after 
laparoscopic cholecystectomy in comparison with conventional cholecystectomy? 
(Chapter 10) 
what are the potential applications of extracorporeal shock waves in surgery? (Chapter 
11) 
The ROGAL Study 
The clinical study investigating extracorporeal shock wave lithotripsy versus cholecystectomy 
was subsidized by the Ministry of Education of the Dutch Government as a medical 
development project. The study was performed at the Department of Surgery of the 
University Hospital 'Dijkzigt', Rotterdam, The Netherlands. Radiologic screening and 
follow-up of patients were performed at the Department of Radiology of the University 
Hospital 'Dijkzigt'. The study protocol was developed with assistance of the Department of 
Clinical Decision Making of the Erasmus University Rotterdam, Rotterdam, The 
Netherlands. The cost-effectiveness analysis was performed in close cooperation with the 
Institute for Medical Technology Assessment of the Erasmus University Rotterdam. The 
study protocol was approved by the Medical Ethics Committee of the University Hospital 
'Dijkzigt' and the Erasmus University Rotterdam. 
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CHAPTER 2 
The current treatment modalities for symptomatic gallstones 
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Abstract 
Gallstone disease is an important clinical problem: approximately 10% of all adults in the 
western population have gallstones. Most gallstones, however, remain asymptomatic and 
from various disciplines there is consensus that only symptomatic gallstones require therapy. 
Since the fIrst gallbladder extirpation in 1882, cholecystectomy has been considered the gold 
standard. Nowadays, this operation is performed laparoscopically in most hospitals. Despite 
relatively low morbidity and mortality rates, a number of alternative therapies have been 
developed in the past few years. These alternative treatment modalities are especially 
indicated in high risk patients and in patients rejecting surgery. In this review article the 
currently available treatment modalities are discussed. 
18 
Introduction 
Gallstone disease is an important clinical problem with tremendous economic consequences. 
About 10% of the adult population have gallstones [1.2] and approximately 500,000 
cholecystectomies are performed annually in the United States [3]. As a consequence, more 
than three million hospital days and one billion dollars are spent on cholecystectomy every 
year [4]. Gallstones cause symptoms in the minority of patients: it is estimated that only lO-
IS % of the patients ever become symptomatic [5]. This understanding led to consensus that 
only symptomatic gallstones require therapy [6-8]. 
Since the first succesful gallbladder extirpation in 1882, cholecystectomy has been 
considered the therapy of choice for symptomatic gallstones [9]. Although cholecystectomy 
has become a routine operation in experienced hands, it is still accompanied by considerable 
morbidity and mortality. This fact led to extensive research for alternative, preferably 
noninvasive, treatment modalities for gallstone disease. 
The different treatment modalities for symptomatic gallstones are discussed in this 
review. The major exclusion criteria for the different treatment modalities are depicted in 
Table 1. 
1. Open cholecystectomy 
In 1882 the first gallbladder extirpation was performed in Germany [10]. Cholecystectomy 
is considered curative but is accompanied by a morbidity of 10-30% and a mortality of 0.1-
0.6% [9,11,12]. Both percentages increase with age, concomitant disease or when the 
procedure is accompanied by common bile duct exploration [II]. Access to the gallbladder 
can be achieved via three different incisions (subcostal, abdominal transverse and midline). 
Reports on which incision is preferable are controversial in terms of postoperative 
complications [13,14]. Therefore, it is in fact the surgeon's preference that determines the 
sort of incision. The most serious complication of cholecystectomy is an accidental bile duct 
lesion, which usually leads to serious morbidity and even mortality [15,16]. Bile duct lesions 
occur in 1-2 per 1000 operations [15] and are related to the surgeon's skill, variations in 
anatomy and inflammatory local conditions [16]. Most bile duct injuries are discovered in 
the postoperative phase [17] and only approximately 20% are discovered intraoperatively. 
This rate increases if a cholangiogram is performed routinely [15,16]. Although the incidence 
of bile duct injuries is related to the surgeon's skill, injuries are not caused by lack of 
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experience. Surprisingly, it was found that most accidental lesions are caused by surgeons 
and surgical trainees, who had performed more than 25 but less than 100 cholecystectomies 
[15]. Hospitalization time for a classic cholecystectomy averages about a week and has 
decreased gradually in the last few years [12]. Even, discharge within 24 h after elective 
cholecystectomy has been described [18]. Except for high anesthesia risk, there are in fact 
no contraindications for classic cholecystectomy (Table I). 
2. Bile acid therapy 
The first attempts to dissolve gallstones by oral medication go back as far as 1937 [19], 
although the concept of dissolving gallstones had already been discussed in 1873 [20]. Almost 
100 yr later, clinical administration of bile acids appeared to be feasible [21,22]. 
Chenodeoxycholic acid (chenodiol or CDC) and its 7fi-epimer ursodeoxycholic acid (ursodiol 
or UDC), have been successful in dissolving gallstones [21-24]. Both bile acids occur 
naturally in humans and several other species. 
The exact biochemical mechanism by which cholelitholysis is achieved, is complex [25]. 
In fact, two main activities are involved: bile desaturation and actual dissolution. The 
mechanism by which UDC and CDC reduce cholesterol saturation and dissolve cholesterol 
gallstones involves enrichment of the bile acid pool with the administered bile acids. 
Furthermore, hepatic cholesterol secretion into bile is inhibited by CDC, because it interferes 
with the cholesterol-synthezing enzyme HMG-CoA-reductase [26-28]. Actual dissolution is 
achieved by transfer of cholesterol into micelles and vesicles. Transfer into micelles is 
enhanced by both CDC and UDC, whereas transfer into vesicles occurs mainly by UDC 
[25]. Finally, UDC is believed to reduce intestinal uptake of cholesterol [28], although 
evidence in this regard is conflicting [29]. 
CDC therapy is associated with several dose-related side effects, such as diarrhea and 
clinically nonsignificant increases in transaminases and serum cholesterol [25,30-33]. UDC 
is not associated with toxic side effects [34], but is more expensive than CDC. For this 
reason, and because side effects of CDC are milder iflow-dosage CDC therapy is combined 
with UDC, in Europe a combination therapy is to be preferred to CDC alone [35]. It is not 
clear whether combination therapy is more effective than UDC alone [36,37]. 
Advised doses are 15 mg CDC/kg/day and 8-13 mg UDC/kg/day, respectively, or 7.5 
mg CDC/kg/day and 6.5 mg UDC/kg/day, if UDC and CDC are combined [25,34,35,38]. 
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Evidence as to whether absorption of UDC is better as a bedtime dose than as a mealtime 
dose is conflicting [39,40]. For CDC and the combination ofUDC and CDC, a bedtime dose 
is advised [26,40-42]. 
UDC seems to be more resistant to bacterial destruction than CDC, which explains why 
UDC is effective at a smaller dose than CDC [43]. It also explains why UDC is less toxic: 
due to less bacterial destruction, less toxic side products, such as lithocholic acid, are formed 
[44]. 
Oral bile acid [OBA] therapy is rather time consuming. Usually, treatment must be 
continued for at least some months and frequently for several years [45]: the rate of decrease 
of gallstone diameter appears to be approximately 1 mm per month [46]. Therefore, stone 
diameter is a major determinant of effectiveness of oral dissolution (46). If the stones are 
smaller than 1 em in diameter, few in number. the cystic duct is patent and the patient is 
compliant with the treatment, the likelihood of success is about 60% [33,47]. This success 
rate decreases when stones are larger or multiple [42,47]. Stones larger than lcm are 
therefore considered a relative contraindication for OBA therapy (48) and stones larger than 
15-20 mm unsuitable for oral dissolution alone [38,47,48]. 
Pregnancy or a planned pregnancy is a contraindication for CDC therapy, which is 
thought to cross the placenta, possibly damaging the fetal liver (49). Opinions on a possible 
teratogenicity of UDC are conflicting [26,50-52), but recently pregnant women with 
intrahepatic cholestasis were treated with UDC successfully, without any adverse effect for 
their babies [53). In conclusion, OBA therapy can be effective, but only in selected patients 
(Table 1). Stone recurrence is a serious problem (discussion). 
3. Contact dissolution 
Local contact dissolution of gallbladder stones is much less time consuming than oral 
litholysis, but is invasive. Nevertheless, it can be performed without general anesthesia [54), 
thus being applicable to high-surgical-risk patients. The solvent most applied, is methyHert-
butyl-ether (MTBE) [54,55), which is also capable of dissolving stones in the common bile 
duct. Several other agents, such as monooctanoin [56], limonene [57] and ethyl propionate 
[58), have also proved to be effective. EDTA has not been tested in vivo, but in vitro studies 
show that EDTA is capable of dissolving cholesterol stones with minor calcifications [59). 
Dissolving agents can be infused via a catheter, which can be installed into the 
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gallbladder either transhepatically [60] or endoscopically [61]. Dissolution can be 
accomplished after repeated cycles of infusion and complete aspiration of the dissolving agent 
[47,53]. Although infusion may take even more than 1 day, median treatment times with 
MTBE are approximately 6 h for solitary stones and 7 h for multiple stones [62]. A pump 
system for automatic delivery of the solvent was recently introduced [63]. 
In vitro comparison of the dissolving capacity of MTBE, monooctanoin, limonene and 
a limonene/monooctanoin mixture showed that MTBE is the most potent gallstone solvent 
now available [64]. In vivo MTBE dissolves gallbladder stones 50 times faster than 
monooctanoin [60]. 
MTBE dissolution therapy is inexpensive [65-67] and very effective: reports show 
dissolution rates as high as 95% [54,68]. Slightly echogenic debris remains in most of the 
cases [54]. Side effects include hemolysis and duO<lenitis in case of overflow and, due to 
systemic absorption, nausea and somnolence. When absorbed, MTBE is eliminated almost 
intact by exhalation [69]. Like oral bile acids, MTBE has been used as adjuvant therapy after 
extracorporeal shock wave lithotripsy (ESWL) [70], but up to now it has not been used 
routinely for this purpose. 
Because of its invasive character and potentially serious side effects, contact dissolution 
should be confined to specialized centers [71]. 
4. Extracorporeal shock wave lithotripsy 
In 1980 the first clinical experience with ESWL for the treatment of kidney stones was 
reported [72]. ESWL has nOw become the therapy of choice in the case of urolithiasis. 
Surgical treatment is restricted to less than 5% of patients [73]. Because of the goO<l results 
in urology, other applications of ESWL have been studied. ESWL for gallbladder stones has 
been applied since 1985 [74,75]. 
Shockwaves are characterized by ultrashort, high-pressure amplitudes and they obey the 
physical laws of acoustics. The shockwaves are focused on the stone and they travel through 
the body without causing severe tissue damage because water, the transmission medium, 
absorbs very little acoustic energy and the acoustical impedance of soft body tissues is close 
to that of water. The shockwave energy is released at the interface of body tissues and the 
stone surface because of the abrupt change of acoustic impedance. This causes tear-and-shear 
forces, which together with the formation of cavitation bubbles on the surface of the stone, 
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lead to progressive stone disintegration [76,77]. 
Shockwaves can be generated by three methods: by an underwater electrostatic spark-gap 
discharge, by electromagnetic generation or by piezo-electric generation [78]. Spontaneous 
passage of fragments up to 5 mm through the cystic duct and the papilla of Vater without 
clinical or biochemical symptoms has been observed [79]. Fragments larger than 5 mm are 
less likely to be cleared spontaneously and this underlines the necessity for adjuvant 
dissolution therapy of fragments [31]. ESWL can be performed under intravenous analgo-
sedation on an outpatient basis [80,81]. The treatment time averages 1 h (range: 26-210 min) 
and usually 1-2 sessions are required [31,75,80-83]. 
ESWL is limited by restricted eligibility, moderate results and the possibility of stone 
recurrence. Suitability for ESWL depends on a large number of conditions, which are 
depicted in Table I. It should be noted, however, that these exclusion criteria are the initial 
criteria of the Munich group [75], and have been widened by other authors [81,84,85], as 
well as by the Munich group itself [80,86]. Due to the rigid entry criteria, only 10-53% of 
the patients are eligible for ESWL [75,80,87-92]. Overall stone free rates at 12 months vary 
between 30 and 78% [75,80,83,84,93], but therapy is found to be more effective for solitary 
than multiple stones, for radiolucent than slightly calcified stones, and for smaller than for 
larger stones [31]. Reliable long-term data on stone recurrence rates after succesful ESWL 
are still not available [80], but medium-term results suggest a recurrence rate of 20% in 4 
yr [94], which is in fact lower than in other alternative, gallbladder preserving, therapies 
[80,81]. Despite these limitations of ESWL and the necessity of adjuvant therapy, morbidity 
and mortality are minimal [75,80,81,84]. ESWL of gallstones is therefore especially 
indicated for patients with a high surgical risk. 
5. Cholecystolithotomy 
Endoscopic removal or lithotripsy of gallbladder stones via a percutaneous transperitoneal 
approach offers the advantage of immediate removal of all stone material regardless of 
number, composition or size (Table I). With sterile techniques, the gallbladder fundus is 
located and punctured under radiologic guidance and analgo-sedation. For about 2 wk, a 
catheter must be left behind for drainage. Percutaneous techniques are technically demanding 
[95] and are therefore performed in a few specialized centers only. 
Success rates of cholecystolithotomy are reportedly up to 95 %, although often more than 
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one stone removal session is necessary [95-101]. Nonfatal complications occur in about 13% 
of the patients [101]. 
6. Rotary contact lithotripsy 
Rotary contact lithotripsy involves the placement of a special instrument. This device includes 
an impeller that rotates up to 30.000 rpm and a six-pronged metal basket for protection of 
the gallbladder wall. While the rotating impeller creates a powerful vortex. that automatically 
pulls the calculi into the basket, fragmentation to concrements < 0.5 mm is easily achieved 
[102]. The procedure takes about 10-60 min, depending on the stone load and stone 
composition [103]. Because of its recent introduction, little information is available on 
morbidity, apart from the encountered drain-related problems. No mortality has been 
reported. 
7. Laparoscopic cholecystectomy 
The first series of laparoscopic cholecystectomies was reported in France in 1987 [104]. 
Under general anesthesia, a pneumoperitoneum is created by insufflation with carbon dioxide. 
Via four abdominal incisions with a diameter ofless than I cm each, surgical instrumentation 
is introduced. In fact the laparoscopic cholecystectomy is a variant of the open 
cholecystectomy. Here, also, the gallbladder is removed after ligation of the cystic duct and 
artery. 
Major advantages of this technique are a markedly diminished need for postoperative 
narcotic analgetics, early discharge from the hospital and a quicker return to work [105-107]. 
The cosmetic result (the absence of a large scar), is expetienced a major advantage. Absolute 
contraindications are sepsis, peritonitis and distended bowels [108]. Relative contraindications 
are previous upper abdominal surgery and an inflamed gallbladder; the two main causes of 
conversion to open cholecystectomy in about 5-10% of the cases [105,109,110]. 
The most serious complication of the laparoscopic cholecystectomy is bile duct injury. 
For the most part, this is the result of misidentification of the common bile duct for the cystic 
duct or inaccurate placement of clips. The reported higher incidence of this complication in 
laparoscopic than in open cholecystectomy gives reason for some concern [105, 111,112]. The 
incidence of common bile duct lesions is expected to decrease after the initial learning curve. 
Other complications are comparable to the open technique, but may cause conversion to an 
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open cholecystectomy, e.g. in case of a laparoscopically uncontrollable arterial bleeding. The 
number of contraindications is thought to decrease as the result of growing experience with 
the technique: already-pregnant women have been treated successfully with laparoscopic 
cholecystectomy in the first and second trimester [1l3]. 
When common bile duct stones are suspected, an intraoperative cholangiography can be 
performed easily [114-116]. When found, one could consider converting to open 
cholecystectomy with common bile duct exploration or performing endoscopic retrograde 
cholangio-pancreatography [ERCP] afterwards. In cases in which common bile duct stones 
are demonstrated in the preoperative work-up, extraction by ERCP can be achieved prior to 
laparoscopic cholecystectomy. Even common bile duct surgery via the laparoscope appears 
feasible [116,117]. Although in most cases laparoscopic cholecystectomy is performed under 
general anesthesia [105,109,110], it is also done under epidural anesthesia [118]. Although 
hospitalization is still the rule, laparoscopic cholecystectomy can be performed on an 
outpatient basis [118,119]. 
Discussion 
Gallstones are of great clinical importance for which different treatment modalities are 
available nowadays. Other methods, such as laser lithotripsy, are still experimental 
[120,121]. 
For more than a century, operative extirpation of the gallbladder has been the therapy of 
choice in case of symptomatic cholelithiasis for two basic reasons. First, cholecystectomy is 
applicable in almost any patient, and second, there is no possibility of stone recurrence. 
Laparoscopic cholecystectomy seems to (re-)confirm this view and, moreover, it has apparent 
advantages over the open technique. Still, critical evaluation of morbidity and mortality of 
this technique are necessary and data on the incidence of bile duct lesions are especially 
important [105,111,112]. 
Alternative methods are less invasive, but both eligibility and results are often limited. 
Besides the necessity for a more extended diagnostic work-up, the largest problem of 
alternative gallstone treatment seems to be stone recurrence, which is estimated to be about 
10%/yr with a stabilization after 5 years [122-126]. However, recurrence is more frequent 
after treatment of multiple stones than of solitary stones [126]. 
It is expected that the laparoscopic cholecystectomy will be the new gold standard [127]. 
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Alternative treatment modalities will then be reserved especially for those patients with a high 
surgical risk and for those patients, who are unwilling to be operated. 
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Table 1 : exclusion criteria for the different treatment modalities for sYmptomatic gallstone disease 
High Acute Slone Stone Negative Calcified Pregnancy Oral Previous 
surgical biliary diameter number OCG2 stones Contra- UAsurgeryl 
risk diseasel (rum) ceptives 
OC ± ± 
ORA + > [5 + + ± ' + 
CD + + + 
ESWL + <5 >3 + + + + 
>30 
PC ± + ± ± 
RCL + >25 + ± ± 
LC ± ± ± ± 
+ absolute contra-indication ; - : no contra-indication; ± relative contra-indication 
OCG = Oral Cholecystography, OC = Open Cholecystectomy, OBA = Oral Bile Acid therapy, CD = Contact Dissolution, ES\VL = Extracorporeal Shock Wave 
Lithotripsy, PC = Percutaneous Cholecystolithotomy, RCL = Rotary Contact Lithotripsy. LC = Laparoscopic Cholecystectomy 
1: acute biliary disease = acute cholecystitis, pancreatitis, cholangitis, choledocholithiasis, 2: negative OCG = non-opacification of the gallbladder, 3: VA = upper 
abdominal, 4: see text 
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CHAPTER 3 
Eligibility for extracorporeal shock wave lithotripsy of gallbladder stones using different 
entry criteria 
P.W. Plaisier, R.L. van der Hul, H.G.T. Nijs, R. den Tocm, D.T. Terpstra, H.A. Bruining 
J Stone Dis 1993;5:125-30 
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Abstract 
Extracorporea1 Shock Wave Lithotripsy (ESWL) was introduced as a nonsurgical treatment 
for uncomplicated, symptomatic gallstone disease. Due to its limited results and the 
possibility of stone recurrence, ESWL is mainly indicated for patients who reject or cannot 
tolerate cholecystectomy. For budgetary and planning purposes, it is essential to know what 
percentage of patients is eligible for this form of therapy. In the literature suitability is either 
reported variably (ranging from 10 to 53%) or not mentioned. We retrospectively assessed 
eligibility for ESWL for different entry criteria, based on the histories of 694 consecutive 
patients, who were referred for gallstone therapy from I April, 1988 to I October, 1991. 
Only 10.3-46.9% of symptomatic patients were found eligible for ESWL, depending on the 
entry criteria used. When the overall results are compared with eligibility, there is no inverse 
relationship. This suggests that patient selection is not the only factor determining the results 
of therapy. It is concluded, therefore, that also other factors, such as treatment schemes, the 
lithotriptors used and experience of the treating physicians, are importants factors for the 
outcome of ESWL therapy. 
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Introduction 
In 1985 Extracorporeal Shock Wave Lithotripsy (ESWL) was introduced as a noninvasive 
treatment for uncomplicated, symptomatic gallstone disease [I]. The first results of large 
series of patients treated with ESWL, were published in 1988 [2]. At first the selection 
criteria, as used by the Munich group [1-3], were adopted worldwide. However, gradually, 
the entry criteria for ESWL became less strict [4-15]. Although some authors suggest that 
proper patient selection is essential for successful ESWL [2,5,16], others consider selection 
criteria arbitrary [4,8,10, II]. 
Eligibility for ESWL has been estimated to be between 10.4 and 53.0% 
[2,3,5,6,10,13,14,17-24]. Obviously, this wide range is a consequence of the fact that 
various selection criteria are used. Also for other reasons these data cannot be compared 
directly: various authors calculated eligibility from different patient groups and data were 
collected in various ways. The aim of this study is to overcome the problem of different 
definitions and different methods of selection, thus contributing to a better deliniation of the 
role of ESWL for gallstone management in general, and the need for lithotriptors in 
particular. Therefore, we calculated eligibility for this treatment modality using various 
selection criteria. These calculations were based on the clinical findings of 694 consecutive 
patients, who were referred to our institute for gallstone therapy and correlated the results 
to the overall results reported by different investigators. 
Patients and methods 
From I April, 1988 tol I October, 1991,694 patients (174 men [25.1 %] and 520 women 
[74.9%]) visited our surgical outpatient clinic for gallstone disease. Four hundred twenty 
patients (60.5%) were referred by their general physician, 155 (22.3%) by specialists, and 
119 (17.1 %) visited the clinic on their own initiative. Mean age was 49.1 ± 15 years 
(median 48; range: 19-88). Twenty patients (2.9%) had an increased operative risk [ASA-
classification III] and 192 were overweight [Quetelet-index >27.0] (27.7%). 
All patients were analysed according to protocol. Special attention was paid to 
symptomatology, concontitant diseases, previous operations, and the patient's preference for 
therapy. Patients were considered symptomatic according to the Roma working group 
definition: pain more than 15 minutes and shorter than 5 hours, usually located in the 
epigastrium and/or right upper quadrant, sometimes radiating to the back, in the absence of 
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other abnormalities which can explain these abdominal complaints [25]. 
At physical examination, special attention was paid to patient's height, weight, blood 
pressure, abdomen, heart and lungs. Laboratory tests consisted of a white blood cell count, 
serum levels of hemoglobin, total bilirubin, cholesterol, alkaline phosphatase, gamma-
glutamyl transpeptidase, aspartate- and alanine aminotransferase and amylase. 
On ultrasonography (US) gallbladder size (normal/contracted/hydrops), number of 
gallstones, diameter of largest stone, gallbladder wall thickening, grit (concrements <3 mm), 
sludge, stone impaction and enlarged common bile duct were noted, if present. On oral 
cholecystography (OCG) contrast in gallbladder and/or small bowel, number of gallstones, 
diameter of largest stone, presence, and extension of calcifications (core/rim/total) and 
buoyancy (the presence of floating stones) were assessed. 
Results of recent examinations done elsewhere were not repeated and used in this study. 
OCG was not performed, when the patient refused ESWL as a therapeutic option or previous 
US examination excluded the patient from ESWL according to our own -wide- criteria: 1- IO 
gallstones with a minimum diameter of 5mm with no calcifications or calcifications of a rim 
< 3mm in symptomatic, non-acute patients with functioning gallbladders [13]. 
All data were collected retrospectively and eligibility was calculated by exclusion (Figure 
I). Eligibility was defmed as a percentage of symptomatic patients, who fulfilled the entry 
criteria for ESWL. The ideal candidate for ESWL, as defined by Sackmann [2,26], was 
regarded a symptomatic, non-acute patient with one non-calcified gallbladder stone with a 
maximum diameter of 20mm. 
Results 
Seventeen patients (2.4%) discontinued analysis: withdrawal from further analysis (12) and 
emergency cholecystectomy in another hospital (5). One hundred three (14.8 %) patients were 
excluded on history: no biliary symptoms (93), coagulation disorder (2), anti-coagulant 
medication (2), pregnancy (I) and pregnancy wish (4). One patient turned out to have had 
a cholecystectomy some IS years before. Fifty six patients (8.1 %) were excluded on 
concomitant biliary disease: suspected choledocholithiasis (n=46); US proven enlarged 
common bile duct (26), disturbed liver function [>2x highest normal value] (18), or both 
(2), or pancreatitis (10). Ninety eight patients (14.1 %) were excluded for ESWL, because 
they preferred cholecystectomy. One hundred and fifty-five patients (22.3%) were excluded 
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Figure I: flow chart for determining eligibility for ESWL 
If) percentage of referred population 
#K) percentage of symptomatic popuJation 
1) ultra~nogrnphy 
2) oml cholecYlitogrnphy 
on US-findings: more than 10 stones (122), no stones (24), diameter of gallstones <5mm 
(9). Another 106 patients (15.3 %) were excluded on OCG-findings; non-functional 
gallbladder (65) and calcifications more than a rim (41). Of the patients with no stones, 9 had 
polyps, 4 a pathological gallbladder wall thickening or adenomyomatosis and II probably 
passed their stones. No patients were excluded due to cysts, aneurysms or lung tissue in the 
shock wave path. 
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TableJ : calculated and reportt:d eligibility for ESWL 
first maximum maximum maximum % eligible % eligible 
author diameter number calcification calculated reported 
(ref.) (mm) in this by authors 
study 
Sackmann (IS) 30 rim 13.4 
Sackmann(2) 30 3 any 17.2 28 
Sackmann (3) 19 
Brink (17) 15 
Magnuson (IS) 19 
Rege (20) 30 3 rim 19.7 45 
Ponchon (7) 25-35' 10 any 20.7 25 
Den Toom (13) 10 rim 27.7 30 
Vanderpool (5) 20 any 30.1 10 
Rawat (9) 10 30.7 
Zeman (10) rim 34.0 53 
Darn (11) 30' any' 46.9 
Ideal 20 any 10.3 
a : only an exclusion...:rilerion if combined 
h: maximum diameter depending on number of ~tonc~ 
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Of the original 694 patients, 159 patients (22,9 %) were eligible for ESWL using our 
selection criteria [13], representing 27,7% of 574 symptomatic patients (Figure I). Eligibility 
for different selection schemes from other authors is depicted in Table L Overall results in 
relation to calculated and reported eligibility are shown in Figure 2. 
Eligibility & Results 
7 
_ E-reported (%) WE-calculated (%) I i stone free ('!o) 
Figure 2: ESWL: rt':SUlts and eligibility 
1: Snckmann (rd. 1115), 2: S:lckmann (~f. 113), 3: Ponchon (ref. liT), 4: Sacknw.nn (ref. 112). 5: DcnToom (ref. #13), 6: 
Zeman (ref. #10). 7: Dnrzi (rd. #11); E = eligibili.ty 
Discussion 
We calculated eligibility for different selection schemes, because the data reported cannot be 
compared directly. Data cannot be compared for several reasons. Different authors defined 
'eligibility' in various ways and collected data in different ways. Some defined eligibility as 
a percentage of a referred population [2,3], and others as a percentage of symptomatic 
patients [13,18]. Sackman et al. [2,3] used pre-treatment radiologic findings, Brink and co-
workers [17] used contents of extirpated gallbladders and Magnuson [18] used both. Selection 
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of the material of patients again renders these studies incomparable [18]: patients were 
referred for gallstone management [13,17], primarily for ESWL [2,3,6,10,22] or contacted 
directly for possible ESWL [5], 
Eligibility for different entry criteria, as calculated by us in 574 symptomatic gallstone 
patients, varies from 17,2-46,9% (Table I), These data are more or less in accordance with 
the eligibility in the literature, as reported by different authors [2,3,5,6,10,13,14,17-24], Our 
data could be applied to all selection schemes without reservations except those three that did 
not use the number of stones as an exclusion criterion [5,10,11]. As we regard 10 stones as 
the upper limit for ESWL, we did not perform an OCG, if US revealed > 10 stones, 
Although in 122 patients US revealed > 10 stones, in 78 cases an OCG was in fact available, 
either because other specialists had them ordered, or because US and OCG were performed 
combined on the sarne day, Of the 44 patients without OCG, 31 were eligible (70%) for 
ESWL using the Darzi and the Vanderpool scheme [5,11], representing those patients 
expected to have a functioning gallbladder, without calcifications more than a rim, We did 
not include these 31 patients in the Zeman scheme [10]: although Rege and co-workers [20] 
did not use the number of stones as an exclusion criterion, they excluded patients on number 
of gallstones, when the total stone load exceeded 50% of the gallbladder volume, Because 
we were not informed of gallbladder volume, we did not regard the 31 patients, expected to 
have functioning galbladders and gallstones without calcifications of more than a rim eligible 
for ESWL, For the aforementioned reasons, especially our calculated eligibility for the 
Zeman scheme must be regarded with caution. 
The most striking discrepancy between reported and calculated eligibility is present in the 
schemes of Rege [20] and Vanderpool [5], Preselection is a possible explanation for the 
difference between our calculated data and the data reported by Rege, for their entry criteria 
differ only from the Sackmann-scheme [2,3] with respect to the presence of a calcified rim, 
explaining the extra 2,5 % of symptomatic patients eligible fa" ESWL, The discrepancy 
between our data and Vanderpool's are most likely due to the fact that many of his patients 
failed to pursue evaluation [5], 
Our patient group largely represents the general gallstone population because the 
traditional risk factors for gallstone disease (female, fat, forty) are highly retrievable, despite 
a large number of asymptomatic patients (n=93 [13,4%])- a number much larger than 
reported elsewhere (6% [2], 5% [20]), It is, however, not likely that this phenomenon has 
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influenced eligibility, for we defined eligibility as a percentage of symptomatic (not: 
'referred') patients, Also, no differences in patient characteristics could be demonstrated 
between the symptomatic group and the asymptomatic group, 
A considerable number of patients refused ESWL as a therapeutic option, Although this 
may have lead to selection, this selection influenced all calculations to the same extent, It is 
of special interest that in II patients with a clear history of biliary colic, no stones or other 
gallblader abnormalities could be demonstrated, as was reported previously [20], 
Narrowing of entry criteria, which should logically go together with a reduced eligibility, 
is surprisingly not automatically accompanied by improvement of the results (Figure 2), This 
is the case for both our calculated data and the suitability reported, Therefore, we conclude 
that selection criteria play only a partial role in determining the overall results of ESWL, 
Although it has been established that size, number, and gallstone composition are major 
determinants of the time of complete clearance [2,20,27], overall results must also be 
dependent on other factors: the lithottiptor used, the treatment scheme (number of shock 
waves and/or energy settings), or the experience of the physicians, Studies comparing the 
results of different lithottiptors [3,15,28] or the results of different treatment schemes [3,15] 
are warranted to further investigate this conclusion, Although relevance of overall results as 
a parameter of ESWL has been discussed previously [20], our data support the idea that 
perhaps only results for 'ideal patients' should be considered instead of overall results, 
Our data confirm that ESWL is applicable in only the minority of symptomatic gallstone 
patients, Moreover, we found that only 10,3% of symptomatic patients can be considered 
'ideal' for ESWL (Table I), Our data also confirmed that US should be the first procedure, 
when screening for ESWL. US is safe and rather accurate in assessing stone load (number 
and diameter of gallstones), If stone load, as assessed by US, does not exceed the maximum 
number, the next step should be an OCG, on which patency of the cystic duct and 
calcifications of stones can be assessed. When the number of stones is abandoned as an 
exclusion criterion, one could consider to have an OCG performed directly, 
Apart from its limited results, the need for adjuvant therapy (with its disadvantages) [29], 
and the possibility of stone recurrence [30], ESWL has also a limited applicability (Table I). 
ESWL will playa less important role than previously thought [31,32]. Its main indication will 
be those symptomatic gallstone patients, who cannot or are unwilling to be operated upon. 
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Abstract 
In the period September 1988 - September 1992, 133 patients (34 0 and 99 9; mean age: 
49 years [range 24-81]) underwent 299 ESWL-sessions with adjuvant oral bile acid therapy. 
Mean number ofESWL-sessions was 2.5 (1-7), mean number of shock waves was 2817 (75-
4000) and mean duration per session was 62 minutes (35-210). Ninety eight p&.ients (73.7%) 
required intravenous analgo-sedation. At last follow-up (mean: 17.7 months [2-46]), 37 
patients (27.8%) are free of stones and 30 (22.6%) underwent cholecystectomy. At 1 year 
after the first ESWL-session, 51.0% of the patients with a solitary stone and 8.3% of the 
patients with 2-10 stones are free of concrements (p<0.0001). Fourteen per cent (6/43) of 
the patients developed recurrent stones. Major complications comprised pancreatitis (n =4; 
3.0%) and acute cholecystitis (n=l; 0.8%). Our results reconfirm that ESWL is safe and 
moderately effective in selected patients. Because of the wide acceptance of the laparoscopic 
cholecystectomy, ESWL shall be confined to patients with an increased operative risk and 
patients, who refuse surgery. Considering the poor results in multiple stones, ESWL should 
be confined to solitary stones. 
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Introduction 
Extracorporeal shock wave lithotripsy (ESWL) with adjuvant oral bile acid therapy is a non-
invasive treatment modality for symptomatic gallstone disease. After ESWL displaced 
surgical therapy of urinary stones, it was introduced in gastroenterology in 1985 [I]. The 
initial results were very promising [2] and inspired us to also use ESWL in our hospital. 
Here, we present our experience in 133 patients. 
Patients and methods 
Our entry criteria for ESWL are depicted in Table I. 
Table 1 : entry criteria for extracorporeal shock wave lithotripsy 
inclu~iQn criteria 
Symptomatic gallbladder stones Oast biliary colic less than 2 yr ago). 
Visualisation of the gallbladder on OCG. 
Up to 10 stones on US, no upper limit for stone diameter. 
Diameter of the largest stone ~5mm on US. 
Radiolucent stones or small calcified rim C<2mm) on OCG. 
exclusion criteria 
Acute biliary disease (cholecystitis, jaundice. cholangitis, 
pancreatitis, hepatitis, or concomitant bile duct stones). 
Elevated serum activity of liver enzymes (>2 times upper margin of 
reference values). 
Aneurysms or cysts in the shock wave path. 
Coagulopathy. 
Pregnancy. 
ASA III/IV. 
Not capable to fulfil follow up. 
oeG "" oml cholecystography. US - ultra~onography. ASA _ classification of opcrative risk according to the American A~~iociation of 
Ane~thesiologist8; yr = yeaN 
In the period September 1988 - September 1992, 133 patients were treated with ESWL. 
Patient and stone characteristics are depicted in Table 2. Patients were analyzed at an 
outpatient clinic according to protocol: patient history, physical examination and -if patients 
were symptomatic according to the GREPCO definition [3]- laboratory tests and radiologic 
examination. All patients were treated with the Lithostar plus' (Siemens, Erlangen. 
Germany), a second generation shockwave lithotriptor, working on the electromagnetic 
principle. 
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Table 2 : characteristics of 133 ESWL patients and their gallstones 
a. paJients 
Age (years) 
oJ2-ratio 
h. gallstones 
1 stone 
2-5 stones 
6-10 stones 
radiolucent 
calcified rim (:;;2mm) 
mean diameter (mm) 
Mean 
49 
0.34 (34/99) 
17 
Range 
24 - 81 
Number Percentage 
70 52.6 
55 41.4 
8 6.0 
!O5 78.9 
28 21.1 
5-40 
Except the first 16 patients, all ESWL sessions were performed on an outpatient basis. 
Session characteristics are depicted in Table 3. Seven sessions had to be stopped. In one case 
because the treatment was too painful! despite maximum analgo-sedation and in 6 cases 
because of a technical failure. 
Table 3 : characteristics of 299 lithotripsy sessions in 133 symptomatic gallstone patients 
Number (%) Mean Range 
Number of ESWL sessions 2.5 1-7 
Number of shock waves 2817 75-4000 
Session time (min) 61.7 35-210 
Requiring anesthesia 98 \13.7) 
*Fentanyl' (mg) 0.102 0.025-0.300 
*midazolam (mg) 3.3 0.3 - 15.0 
Positioning 
*supine 80 (26.8) 
*left oblique 185 (61.8) 
*both 34 (11.4) 
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Adjuvant treatment with oral bile acids (OBA) consisted of a combination of urso- and 
chenodeoxycholic acid (7-8 mg/kg body weight), taken as a bedtime dose, starting the day 
after the first ESWL session. Ultrasonography was performed 10 days after each ESWL 
session, each 3 months and once per year if the patient was free of concrements. Patients 
were considered stone free, if two consecutive ultrasound examinations could not demonstrate 
any concrements. 
Median and mean follow-up were both 17.7 ± 11 months (range: 2-46); it should be 
noted that follow-up stopped when a patient underwent cholecystectomy. The results of 14 
patients, treated in the period April - September 1988, were excluded from analysis since 
they were treated with another machine. Statistical analysis was performed with a standard 
test for comparing proportions assuming binomial distributions. 
Results 
The results at final follow-up are depicted in Table 4. 
Table 4 : results at last follow-up in 133 patients treated with ESWL 
no fragmentation 
decrease in diameter largest stone < 25 % 
decrease in diameter largest stone 25% < x < 50% 
decrease in diameter largest stone> 50% 
grit (all concrements < 3mm) 
free of concrements with ESWL and OBA 
cholecystectomized 
stone recurrence 
total 
Number 
8 
12 
7 
21 
12 
37 
30 
6 
133 
ESWL "" extrncorporelll shock wnve lithotrip~y: OBA "" oral bile ncid therapy_ 
Percentage 
6.0 
9.0 
5.3 
15.8 
9.0 
27.8 
22.6 
4.5 
100 
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Analysis of the results at 1 year after the first ESWL-session are as follows. The overall 
stone free rate is 27.9% (31/111). The stone free rates of patients with solitary stones and 
2-10 stones are 51.0% (26/51) and 8.3% (5/60). respectively (p<0.0001). Stone free rates 
of patients with radiolucent stones and stones with a calcified rim are 30.9% (29/94) and 
11.9% (2/17), respectively (p=0.10). Of the patients with stones with a diameter ,;20mm 
and > 20mm, eventually 30.9% (30/97) and 16.7% (6/36) became free of stones (p=O.IO). 
Of 43 patients, who had ever become free of stones, 6 (14.0%) developed recurrent 
stones. In all cases the stones recurred within 12 months after discontinuation of OBA 
therapy. Only one patient had stone recurrence after treatment of a single stone; the others 
had multiple stones, before ESWL. In 4 cases the recurrent stones were a-symptomatic and 
not treated. In 2 patients they caused biliary colics and these patients were treated with oral 
bile acids (Ix) and cholecystectomy (Ix). ESWL-related complications are depicted in Table 
5. another 15 (11.3%) patients suffered from OBA-related diarrhea. In all cases, the 
complaints vanished after reducing the dose of chenodeoxycholic acid. 
Table 5 : complications in 133 patients treated with ESWL 
Colics 
Common bile duct obstruction 
jaundice/white stool 
pancreatitis 
Hematuria 
Acute cholecystitis 
Total 
Discussion 
Number 
57 
9 
2 
69 
5 
4 
Percentage 
42.9 
6.8 
3.8 
3.0 
1.5 
0.8 
50.4 
Cholecystectomy is the unchallenged standard treatment for symptomatic gallstones [4,5]. 
Although gallbladder extirpation is more or less a routine operation, it harbors considerable 
morbidity and mortality rates, 10-30% and 0.1-0. 3 %, respectively [4,6]. These rates together 
with the considerable costs accompanying cholecystectomy, were the reason for extensive 
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research in alternative, preferably non-invasive treatment modalities for gallstone disease [7]. 
Of these alternatives, ESWL is applied most. 
In 1988, the first large series of patients treated with ESWL appeared in the New 
England Journal of Medicine [2]. The results were very promising, since -at a minimal 
complication rate- 30, 48, 63, 78 and 91 % of the patients became free of stones at 0-2, 2-4, 
4-8, 8-12 and 12-18 months, respectively. Eventually, it became evident that the initial 
results could not be reproduced [8-10], not even by the Munich group [11]. 
Our overall results are lower and our cholecystectomy rate higher than in other reports 
[8-11]. Our low overall stone free rate is most probably due to our wide entry criteria. Our 
results in solitary stones are highly acceptable. Our high cholecystectomy rate is definitely 
caused by the introduction and consequent acceptance of laparoscopic cholecystectomy [5]. 
The fact that the differences in the results of the different stone types were not statistically 
significant, is probably a type II-error caused by small numbers: the differences were indeed 
evident. Moreover, the significances were demonstrated convincingly elsewhere [12,13]. 
OUf recurrence rate and our finding that most recurrent stones remained a-symptomatic 
is in accordance with the literature [14]. Also that stone recurrence is more frequent after 
treatment of multiple stones than of solitary stones, has been reported earlier [15]. 
We conclude that ESWL is relative effective and safe in selected patients. In general 
practice, however, ESWL is surpassed by laparoscopic cholecystectomy. As a result, ESWL 
shall be confined in the future, to patients with a high operative risk and patients who refuse 
surgery. Considering the reasonable results in patients with solitary stones and the low major 
complication rate, this seems justified. ESWL should be confined to solitary stones. 
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Abstract 
A randomized study was performed comparing extracorporeal shock wave lithotripsy (ESWL) 
with conventional cholecystectomy for uncomplicated symptomatic gallstones. The primary 
outcome of the study was the influence of therapy on biliary colies and gastrointestinal 
symptoms. In the period October 1989 - March 1992, 26 patients were randomized for 
cholecystectomy and 23 for ESWL. Pain diaries and symptom questionnaires were taken 
before, and 3, 6, 12, 18 and 24 months after therapy. ESWL patients regularly underwent 
ultrasound examination for determining stone clearance. Median follow-up was 18 months 
(12-24). Biliary colics were cured in 90.9% and 45.4% of the patients within 3 months after 
cholecystectomy or ESWL, respectively (p<O.OI). Trend analysis showed that both fatty 
food upset and stomach swelling improved significantly after cholecystectomy, while nausea 
improved after ESWL. In five other gastrointestinal symptoms, no significant differences 
could be detected. It is concluded that cholecystectomy is superior to ESWL in improving 
biliary colics, fatty food upset and stomach swelling. Since ESWL is, furthermore, not able 
to clear all stones and harbours the possibility of stone recurrence, cholecystectomy remains 
the preferred treatment modality in healthy patients with uncomplicated symptomatic 
gallstones. 
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Introduction 
The initial results of ESWL of gallbladder stones were very promising [1,2]. The fact that 
all studies on ESWL were observational, inspired us to conduct a randomized trial comparing 
ESWL of gallstones with conventional cholecystectomy, the gold standard [3]. 
We considered that the outcome of such a study should be measured in terms of biliary 
colics and not merely in stone clearance, since biliary calles are considered a manifestation 
of uncomplicated biliary stone disease. We also evaluated the course of eight gastrointestinal 
complaints in the two treatment arms. 
The aim of this study was to compare the frequency and severity of biliary pain and 
gastrointestinal complaints after ESWL with those after open cholecystectomy. 
Patients and methods 
In the period October 1989 - March 1992, 491 patients visited our surgical outpatient 
gallstone clinic. Asessment for eligibility was according to protocol: a history was taken and 
a physical examination was performed. Patients were diagnosed as either 'symptomatic' or 
'a-symptomatic', using the GREPCO-definition [4]. Asymptomatic patients were excluded 
immediately and did not receive therapy (n=80). 
Symptomatic patients underwent further analysis: laboratory tests and radiological 
examination. Objective of this analysis was to exclude patients with local and general 
complications of gallstone disease, such as bile duct stones, pancreatitis, gallbladder polyps, 
mucoceles and non functioning gallbladders. These patients were excluded because these 
conditions require a therapy other than ESWL and, therefore, could not be included in the 
study. So, laboratory tests consisted of liver function tests, serum amylase and a white blood 
cell count. Radiological examination consisted of ultrasonography (US) and oral 
cholecystography (OCG). An OCG was not performed if the patient refused ESWL as a 
therapeutic option or if a previous US examination already excluded the patient from our 
entry criteria for ESWL (Chapter 4; Table 1). At the end of analysis, all eligible patients 
(n=87), were informed about the study and were asked for consent to be randomized. 
Randomization was stratified on number of stones (1, 2-5, 6-10), so that patients were 
randomly divided into one of the two treatment groups on a 1: 1 basis. The randomization 
procedure was computerized and performed at the trial office immediately after the consent 
for randomization was given. Forty-nine patients (56.3 %) consented in randomization. Their 
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characteristics are depicted in Table I. After a 6 month-intake period, in which no patient 
could be randomized, intake was stopped in March 1992. 
Table I: patient characteristics of 49 faI".domized patients in a study comparing extracorporeal shock 
wave lithotripsy with conventional cholecystectomy 
E-group 
age {years] 50.3 ± 12.5 
range 32 -75 
a IQ-ratio 4119 
Q-index >27.0 (%) 26.1 
1 stone 13 
2-5 stones 9 
6-10 stones 
total number of patients 23 
E-group : extrncorporenl shock wave lithotripsy-group 
C-group : cholccY~1CC!Omy-group 
Q-index : QuetdCI.index [weight (kg)/length {m):]. 
C-group 
49.8 ± 12.8 
30 -74 
6/20 
27.3 
12 
12 
2 
26 
Shock wave therapy was performed with the Lithostar Plus' (Siemens AG, Erlangen, 
Germany), a second generation lithotriptor, working on the electromagnetic principle. 
Treatment was performed at maximal energy level Oevel 9) and the patients were treated in 
left oblique or supine position. ESWL was performed as an outpatient procedure. ESWL 
patients were adjuvantly treated with oral bile acids (OBA) in a combination of urso- and 
chenodeoxycholic acid (7-8 mg/kg body weight). OBA medication was taken as a bedtime 
dose, starting the day after the first ESWL session. US was performed 1-2 weeks after each 
ESWL session and 3, 6, 12, 18, 24 months after the first ESWL-session. If US revealed 
stones with a diameter > 5mm, another ESWL-session was performed as soon as possible 
(usually within I week after this US). If concrements larger than 5mm were found after 3 
ESWL-sessions, the patient was advised to undergo cholecystectomy. Patients were 
considered stone free, if two consecutive US examinations, with an interval of 3 months, 
could not demonstrate any concrements. After the second US that could not demonstrate 
concrements, OBA-medication was stopped. 
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Cholecystectomy 
Cholecystectomy was performed by laparotomy, via a subcostal incision. It was performed 
under general anesthesia, as an inpatient procedure. Intra-operative cholangiography was not 
performed routinely. 
Follow-up 
Follow-up consisted of self-administered so-called 'pain diaries' covering the periods 0-3, 3-
6, 6-12 and 12-18 months. When patients experienced biliary colics, they had to f11l out the 
date, the duration and severity (mild, moderate or severe) on these diaries. Analogously to 
the definition of biliary colic, only pain epsiodes longer than 30 minutes were considered. 
The patients also self-administered questionnaires, taken before therapy (t=O) and at 3, 
6, 12, 18 and 24 months after therapy. On these questionnaires, the patients had to score 
whether they suffered from the following gastrointestinal . omplaints: nausea, fatty food 
upset, vomiting, stomach swelling, pyrosis, belching, constipation and diarrhea. Scoring was 
performed on a semi-quantative scale (absent, mild, moderate or severe). Both questionnaires 
and pain diaries were sent by mail in all patients and double-checked I month after receipt. 
Double-checking was performed by interviews, taken at the outpatient clinic for ESWL-
patients. In the cholecystectomy-group, the first 5 patients were checked at the outpatient 
clinic and the next 5 by telephone. Since no differences were found between patients checked 
at the outpatient clinic and patients interviewed by telephone, the remainder of the 
cholecystectomy-patients (n=16) were checked by phone. 
Statistics 
Statistical analysis was done with the Chi-square test (McNemar version), the Chi-square test 
for trend, the semi-quantative test of Yates-Cochran and the test for comparing proportions 
assuming binomial distributions. Analyses of the pain diaries and the symptom questionnaires 
were performed on an intention-to-treat basis. Analysis of the efficacy of ESWL in terms of 
stone clearance were per protocol, i.e. based on the data of all patients undergoing ESWL. 
Results 
Forty-nine patients were randomized, 23 for ESWL (E-group) and 26 for cholecystectomy 
(C-group). Four patients expressed second thoughts after they had initially consented in 
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randomization. These patients were all C-group patients. Median follow-up was 18.0 months 
(range: 12-24). No patient was lost to follow-up. 
ESWL 
Since four patients, who were randomized to cholecystectomy, preferred ESWL, eventually 
27 patients underwent lithotripsy. Fourteen patients had a solitary stone and 13 had 2-10 
stones at baseline. Mean number ofESWL-sessions was 2.3 ± 1.0 (median: 2; range: 1-4). 
Mean number of shock waves per session was 2882 ± 394 (median : 3000; range: 1225-
3500). At 18 months follow-up, 13 patients (48%) were free of stones, 2 (7%) had minimal 
debris (concrements <3mm) and 6 (22%) still had concrements. Another 6 patients (22%) 
had undergone cholecystectomy because of persistent biliary colics (n =4), acute cholecystitis 
(n=l) and pancreatitis (n=I). The 2 patients with complications after ESWL, were both 
operated within 3 months after the first ESWL-session. The 4 patients who were operated 
because of unsuccessful ESWL, were all operated within 12-15 months after the first 
lithotripsy. Of the 14 patients with solitary stones at baseline, 9 (64%) eventually became 
free of concrements, 3 (21 %) still have concrements and 2 (14%) were operated after ESWL. 
Of the 13 patients with multiple stones, these figures were 4 (31 %),5 (38%) and 4 (31 %), 
respectively. The differences in likelihood to become free of stones or operated, were not 
statistically significant: p=0.08 and p=0.30, respectively. Of the 13 patients who became 
free of concrements after ESWL, one (8 %) developed recurrent symptomatic stones that were 
successfully treated with OBA. Overall median duration of OBA-treatment was 8 months 
(range 1-24). Median duration ofOBA-treatment in the subgroup of patients, who eventually 
became free of concrements by ESWL, was 6 months (range: 3-18). In no case OBA's had 
to be stopped because of abdominal discomfort, rising liver function tests or elevated serum-
cholesterol. There was nO mortality after ESWL. 
Cholecystectomy 
Twenty-two patients underwent conventional cholecystectomy as the first procedure. There 
was no mortality. Median hospitalization time, including the days of admission and 
discharge, was 8 days (range: 4-12). Another 6 patients underwent cholecystectomy 
secondary to ESWL. Median hospitalization time in this group was 7.5 days (range: 4-35) 
and cholecystectomy was performed laparoscopically in 5 patients. The patient who 
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developed pancreatitis accounted for the hospitalization time of 35 days and she had a 
conventional cholecystectomy with intraoperative cholangiography. Postoperatively, one 
patient had to be observed for 6 hours at an intensive care unit for an epileptic insult. Eight 
months after cholecystectomy, one patient was re-admitted because of common bile duct 
stones. Hospitalization time was 8 days and the patient was successfully treated with 
papillotomy and endoscopic extraction. One patient suffered from wound dehiscence, treated 
conservatively. Two patients complained of persistent scar pain. 
Pain diaries and symptom questionnaires 
Questionnaires and pain diaries were returned and filled out correctly in 92.7% and 89.8%, 
respectively. 
a. pain diaries 
The number of patients complaining of biliary colics after treatmen. are depicted in Table 2. 
Colics were reported less frequently directly after cholecystectomy, while after ESWL they 
remained present in about half the cases for the first 3 months (p<0.01). Thereafter, a 
marked improvement occurred in the period 3-6 months in the E-group. Compared to 0-3 
months, this improvement was statistically significant (p<0.001). After 6 months, no 
decrease in frequency in biliary colics could be demonstrated in both groups. Overall, a clear 
trend of improvement was found in the E-group (p<0.001). No trend could not be 
demonstrated in the C-group, because the colics were already cured immediately after 
treatment. During follow-up, 14 patient.s reported colics: 2 after cholecystectomy and 12 after 
ESWL. Of these 12 ESWL-patients, 11 had stones demonstrated at US, while in 1 patient 
no stones could be demonstrated. Of the patients with biliary colics after cholecystectomy, 
one had common bile duct stones. The other was treated expectantly at her request. She did 
not have elevated liver function tests. 
b. symptom questionaires 
The reported frequencies of fatty food upset, nausea and stomach swelling are depicted in 
Table 3. 
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Table 2: The number of patients complaining of moderate or severe biliary colics (;;:: 0.5 bour) in 22 patients 
undergoing ESWL and 22 undergoing conventional cholecystectomy [analysis per protocol1.ln both treatment 
groups, all patients experiencOO at least one biliary colic before therapy. 
Period E~group 
(months) (0) 
Ox 
'" Ix total 
0-3 10 12 22 
3-6 20 2 22 
6-12 20 21 
12-18 18 0 18 
)(2 for trend: p<O.OOl 
y-c 
p-value 
<O.OI R 
NS 
NS 
NS 
Ox 
20 
21 
20 
16 
C-group 
(0) 
~ Ix total 
2 22 
22 
2 22 
2 18 
XZ for trend: NS 
E-group "'" ESWL-group; C-group _ cholccystectomy-group; Y-C - Ylltes-Cochran test between groups [E vs. C] at ecrtninperlods: NS "" 
not significant; .. ) p <0.05 if adjusted according to Bonferroni 
Trend analyses showed that both fatty food upset and stomach swelling improved significantly 
in the C-group, while nausea improved significantly in the E-group, Between the E- and C-
group there was only at one occasion a signiflcant difference in reponed frequency: for fatty 
food upset at 18 months (p<0,05), in favour of cholecystectomy. For vomiting, pyrosis, 
belching, constipation and diarrhea, no differences were found in reported frequencies 
between before and 3, 6, 12, 18 months after therapy. Nor were there any significant 
differences between the E- and C-group at any time. Analysis of the total number of 
moderate or severe complaints per patient showed also no difference between the two groups. 
Gastrointestinal complaints and stone clearance 
There was no relationship between stone clearance and gastrointestinal symptoms in the E-
group at 12 months after therapy. 
Stone clearance and background variables 
In the E-group, there was no significant difference between the frequency of patients 
eventually becoming free of concrements on one hand and sex, number of stoneS(1 vs. > I), 
diameter of stones ($ 15mm vs. > 15mm), stone calcifications (none vs. $ 2mm), age ($50 
vs. >50 yrs) and body mass index ($25 vs. >25) before therapy on the other hand. 
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Table 3: Comparison in reported frequencies (in %) of fatty food upset. nausea and stomach swelling 
between patients randomized to ESWL and cholecystectomy Iintention-to-treat analysisJ. 
time fatty food 
(months) 
o 
3 
6 
12 
18 
E 
35 
33 
15 
26 
22 
X' for trend: NS 
upset 
C EtC 
44 NS 
21 NS 
29 NS 
13 NS 
0 <0.05 
<0.01 
E '" ESWL (cxtracorporeal shock wave lithotripsy) 
C "" conventional cbolccystcclomy 
EtC = Chi-square te~t between therapic~ 
NS '" not significant 
Discussion 
E 
30 
19 
0 
10 
0 
<0.01 
nausea stomach 
swelling 
C EtC E C EtC 
33 NS 35 48 NS 
13 NS 29 29 NS 
13 NS 20 13 NS 
26 NS 11 10 NS 
6 NS 28 18 NS 
NS NS <0.02 
Many reports have already been published on biliary and gastrointestinal symptoms in 
relation to gallstones and gallstone therapy. Most studies, however, are retrospective [5-7], 
while others are prospective but not controlled [8,9]. Usually they do not compare different 
treatment modalities [6-11] and sometimes include emergency surgery [7,12], common bile 
duct explorations [6,7,12] and procedures concomitant to cholecystectomy [6]. Reports on 
symptomatology after ESWL are scarse and usually report exclusively on patients who 
became free of stones, which is only the minority of treated patients [9]. These different 
designs make comparison difficult. Our study was performed to overcome these methodologic 
problems and it is therefore regrettable that the number of patients is limited. The limited 
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patient entry was caused by several factors. At first, eligibility for ESWL (and thus for the 
study) was limited [13]. Also many patients had a specific preference for one of the treatment 
arms, hampering randomization: outside the context of our trial, another 90 patients, who 
refused randomization, were treated with ESWL. Especially preference for laparoscopic 
cholecystectomy, which was introduced during OUf study, impaired randomization almost 
completely (unpublished observations). Still, follow-up of this study is adequate, so 
conclusions may be drawn from the results. Furthermore, another 23 patients were followed 
in addition by the same protocol without being randomized. Their results were equal to those 
of the randomized patients (not shown), making the effect estimates even more precise. 
Our study demonstrated that biliary colics respond to both ESWL and cholecystectomy. 
Since both treatment modalities are relatively safe, we confirmed that treating symptomatic 
gallstone patients is highly justifiable [7,8]. Cholecystectomy, however, cures biliary colics 
more consistently and some 3 months earlier than ESWL, making it superior to ESWL. 
We also found that fatty food upset and stomach swelling responded to cholecystectomy. 
Nausea improved after ESWL. These responses take, however, at least 6 months. 
Furthermore, 5 other gastrointestinal symptoms did not respond to either form of treatment. 
Finally, we found in the E-group that whether a patient was free of concrements or not, did 
not influence the frequency of reported gastrointestinal symptoms. However, it cannot be 
excluded that the results of this subgroup analysis may be subject to a type II-error, because 
of the limited number of patients. Still, our findings support the notion that gastrointestinal 
symptoms are most probably not related to the presence or absence of gallstones and, 
therefore, should not be used as an indication for elective gallstone therapy [4,11,14-17]. 
To our lmowledge, there is only one report that investigated symptornatolgy after ESWL 
and conventional cholecystectomy in a randomized way as we did, although the objective of 
that particular study was a cost-effectiveness analysis [18]. Also in this series, only patients 
with uncomplicated symptomatic gallstones were studied. However, on other points, our 
study differed from that of the Sheffield-group. Our lenght offollow-up, stone clearance rate 
and complication rates compare favourably. Moreover, we used a different kind of 
lithotriptor and performed ESWL solely on an outpatient basis. Also, we did not have a 
subgroup of patients treated with lithotripsy alone, but treated all patients adjuvantly with 
OBA after ESWL, which is superior to ESWL alone [19). Finally, we did not treat heavily 
calcified stones. 
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Despite these apparent differences, our fmdings are surprisingly concordant. Also in the 
report of the Sheffield-group, a significant difference in pain experience post-treatment could 
be demonstrated in favour of cholecystectomy. Also, no consistent patterns of differences 
between cholecystectomy and lithotripsy could be demonstrated in gastrointestinal symptoms: 
if differences were observed, they were usually small and there was some evidence that 
cholecystectomy produced a greater reduction in a small subset of gastrointestinal symptoms 
than ESWL Finally, also here, stone clearance was not related to self-reported 
gastrointestinal symptoms. 
The results of a randomized study comparing ESWL with laparoscopic cholecystectomy 
were published only recently [20]. The studied population is remarkably identical to ours 
regarding age and sex and in this trial, colics recurred in 57% of the patients after ESWL. 
The authors stress that in 26% of these patients, colic caused a day away from usual 
activities. Like us, they also demonstrated that cholecystectomized patients may suffer from 
biliary colics. It should be noted, however, that this occurs in only the minority of patients 
(2/25). Finally, it is noteworthy that also here, a considerable number of patients crossed 
over from one treatment group to the other. 
Our treatment protocol differed from most ESWL protocols regarding the start of OBA 
administration. Where we started OBA therapy after the fIrst ESWL session, most protocols 
began two weeks prior to ESWL in order to achieve cholesterol desaturation prior to 
lithotripsy [1,2,18]. However, because OBA therapy is accompanied by a prolonged 
gallbladder emptying [21,22], we considered it theoretically more advantageous to start with 
OBA later. In this way, the gallbladder would have the opportunity to clear most (or at least 
some) of the smaller fragments that occur after lithotripsy, by natural expUlsion [9]. The 
disadvantage of reaching cholesterol desaturation two weeks later in other protocols, was 
considered to be of little importance since OBA therapy has usually to be maintained for 6-12 
months. 
Our overall stone clearance rate is relatively low compared to other reports [2]. This is 
most probably due to the fact that we treated up to 10 stones, where others usually treat not 
more than three stones [2]. We discussed this fInding already in a previous report on 83 
patients treated with ESWL [23]. In fact, we now recommend to treat only radiolucent, 
solitary stones because of the poor clearance rates for multiple stones [24]. 
Considering our results and the fact that cholecystectomy is not accompanied with 
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gallstone recurrence, we conclude that cholecystectomy is to be preferred to ESWL. Our 
finding that also ESWL can be accompanied by severe complications and that nearly a 
quarter of the patients eventually undergo cholecystectomy support this conclusion. 
However, as long as patients satisfy strict entry criteria, there should be no objection against 
patients' preference for ESWL, although it is not as cost-effective as cholecystectomy [18,25-
27]. In patients with an increased operative risk, ESWL may still offer a solution. 
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CHAPTER 6 
Quality of life after gallstone therapy: results of a randomized study comparing 
lithotripsy with open cholecystectomy 
P.W. Plaisier. R.L. van der Hul, H.G.T. Nijs, R. den Toom, O.T. Terpstra, H.A. Bruining 
Eur J Surg (accepted for publication) 
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Abstract 
A randomized study was conducted in order to compare quality of life after extracorporeal 
shock wave lithotripsy (ESWL) and open cholecystectomy, the gold standard. In the period 
October 1989 - March 1992, 23 patients were randomized to ESWL and 26 to open 
cholecystectomy. Health questionnaires were filled out before and at 3, 6 and 12 months after 
therapy. Median follow-up was 18 months. Both treatment modalities improved quality of 
life. Open cholecystectomy improved quality of life significantly better than ESWL during 
the course of one year. It is concluded that open cholecystectomy is superior to ESWL in 
improving quality of life. Therefore, cholecystectomy remains the therapy of choice for 
symptomatic gallstones. However, in patients who are unfit or unwilling to undergo surgery, 
ESWL is an adequate form of treatment because the majority of patients tend to benefit from 
it in terms of quality of life. 
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Introduction 
When extracorporeal shock wave lithotripsy (ESWL) was introduced as a promising 
alternative to cholecystectomy, it was obvious that it was not suitable to treat all stones. It 
also harboured the potential risk of stone recurrence. Considering this theoretical 
disadvantage of ESWL, the outcome of an evaluation of ESWL should be measured in other 
terms than merely in terms of stone clearance. Ideally, such a study should be conducted as 
a randomized trial, comparing ESWL with open cholecystectomy, the gold standard [1,2]. 
We conducted such a trial to detect any differences in terms of quality of life between ESWL 
and conventional cholecystectomy. For the methods and results of ESWL and 
cholecystectomy is referred to Chapter 5 of this thesis. 
Patients and methods 
From October 1989 - March 1992, 49 patients were randomized, 23 for ESWL (E-group) 
and 26 for cholecystectomy (C-group). Randomization was performed by computer after 
stratification for number of gallstones (1, 2-5, 6-10 stones). Patients were recruited from a 
so-called 'gallstone clinic', a surgical outpatient clinic, solely for gallstone patients. Inclusion 
and exclusion criteria for the study were the same as the entry criteria for ESWL, as depicted 
in Chapter 4 (Table 1). Patients were diagnosed as 'symptomatic' gallstone patients when 
they met the GREPCO-definition [3]. After a 6 month-intake period, in which no patient 
consented in randomization, patient intake was stopped in March 1992. 
Follow-up 
Follow-up consisted of self-administered health profile questionnaires, taken before therapy 
(t=O) and at 3, 6 and 12 months after therapy. A validated, translated version of the 
Nottingham Health Profile (NHP) was used [4]. The NHP is a questionnaire which assesses 
6 aspects of quality of life (so-called 'dimensions'), being: physical mobility, pain, sleep, 
energy, social and emotional reactions function. Each domain of these dimensions contains 
items of questions requiring a 'yes' or 'no' answer (dichotomous). If all questions are 
answered 'yes', the patient scores highest, but is considered having the least quality of life. 
A weighting system is derived from extensive validation excercises, so that a positive 
response for each item is multiplied by a factor before aggregation. Hence, besides the 
summing up of the scores for individual items, also weighted scores can be calculated taking 
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the individual weight of each question and/or each dimension into account. 'Health gain' can 
than be defined as the decrease in median score (ergo: the median decrease in positively 
answered questions). NHP's were sent by mail and double-checked I month after receipt. 
Double-checking was performed by interviews, taken at the outpatient clinic (E-group) and 
by phone (C-group). 
Statistics 
Statistical analysis was done with the non-parametric Friedman's analysis of variance and the 
Chi-square test for comparing proportions. Analyses were performed on an intention-to-treat 
basis. 
Results 
Characteristics of the randomized patients were already depicted in Chapter 5 (Table I). 
Mean follow-up was 19.0 months (median: 18.0; range: 12-24). There were no differences 
between the two groups at baseline. No patient was lost to follow-up. 
Quality of life 
NHP-questionnaires were returned and filled out correctly in 96% of the cases. So, from 23 
E-group and 24 C-group patients, data were available before and 3, 6, 12 months after 
therapy. There were no significant differences between intention-to-treat analyses and 
analyses per protocol. 
It was found that the median overall percentage of items answered positively, decreased 
in both treatment groups after therapy (Figure I). However, these decreases were more 
profound and significant for the C-group during the course of I year (p <0.01) compared to 
the E-group (Table I). Table I also shows that the decrease in median percentage of 
positively answered questions is mainly accounted for by the questions from the pain, energy 
and emotional reaction dimensions. Of these three, only the pain and the emotional reaction 
dimension were statistically significant (p<0.05). Health gain was also found in the C-group 
after scores weighted for items alone and items and dimensions (both: p<O.OI). Health gains 
in the E-group for both weighted calculations were not statistically significant. 
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HEALTH GAIN AFTER THERAPY 
Differences in median score (%) 
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Treatment 
Figure 1: Median total scores (in %) on Nottingham Health Profiles; on the abcissa: months 
ESWL : cxtrncorp<lreal shock wave lithotripsy 
ECTO : cholecystectomy 
Table 1: health gain (in %) at 12 months after therapy (defined as the difference in median scores on the quality 
of life questionnaires compared to the situation before therapy), divided into the different dimensions; analsis 
via intention-to-treat; underlined are statistically significant p-values 
E-group (n=23) 
Health F riedm.an • s 
Dimension gain test: 
in 1 year p-value 
energy 0.0 0.503 
pain 5.8 0.319 
emotions 7.2 0.281 
sleep 12.5 0.440 
social 0.0 0.742 
mobility 0.0 0.849 
total 10.5 0.113 
E-group : extracorporenl shock wave lithotripsy-group 
C-group : choh:c)'8te(:tomy~group 
C-group (n=24) 
Health Friedman's 
gain test: 
in 1 year p-value 
26.0 0.065 
12.9 0.034 
17.0 0_035 
12.6 0.284 
0.0 0.853 
11.2 0.565 
17.1 0.003 
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Discussion 
Open cholecystectomy has been the standard operation for gallstone disease for over a 
century. It has tremendous clinical and economical consequences: e.g. in the United Kingdom 
and Ireland to 50,000 cholecystectomies are performed each year [5]. Since cholecystectomy 
is accompanied by a certain morbidity [1], ESWL was introduced as an alternative to 
cholecystectomy with very promising results in a series of 175 patients [6]. 
Both cholecystectomy and ESWL are accompanied by low mortality rates. Therefore, 
using mortality rates to detect any difference between the two treatment arms is insensitive 
and thus inappropriate [7-9]. Especially, minimally invasive surgery is an area well suited 
for quality-of-life research [9]. So, when we started our study, health status-analysis was 
considered a good method since especially in the treatment of symptomatic gallstones, 
improving the patient's quality of life is always be the most important aim of intervention 
[10]. In fact, any form of elective surgery is directed primarily to improvement of quality 
of life, i.e. the relief of disability, discomfort and disfigurelOent [7, II]. 
We chose the Nottingham Health Profile, since it is well validated and one of the most 
widely used general measures of quality of life [8]. Moreover, it has shown reliable in a 
large number of different fields of medicine and surgery, can be easily administered by mail 
and makes relatively small demands on patient time and effort [8,9,12]. Health questionnaires 
not only enabled us to assess the outcome of gallstone therapy but also enabled us to compare 
different treatment modalities. 
We found that both ESWL and cholecystectomy improved quality of life, when measured 
with the NHP and justified the treatment of symptomatic gallstone patients. However, in the 
e-group the health gain was significantly better. This improvement was found in weighted 
and unweighted NHP-scores and mainly in the pain and emotional reactions dimension. The 
influence of the two treatment modalities on quality of life is identical to the influence on 
symptomatology. Also specific gallstone symptoms respond to both treatment modalities and 
this response is more pronounced after cholecystectomy than after ESWL [13,14]. Based on 
these data, the fact that ESWL only clears stones partially and because ESWL is 
accompanied by the possibility of stone recurrence, open cholecystectomy is superior to 
ESWL. Our finding that still nearly a quarter of the patients eventually undergo 
cholecystectomy, finally, supports tItis conclusion. 
To our knowledge, there is only one report that investigated quality of life after ESWL 
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and cholecystectomy, although the main objective of this report was a cost-effectiveness 
analysis [13). In this report both therapies improved quality oflife significantly in most NHP 
dimensions, while there were no differences in median health status in the two groups in any 
dimension at 12 months. A possible explanation of the fact that we did not fmd any 
statistically significant differences in health gains in patients treated with ESWL, is that we 
did not have a sub-group of patients n6t adjuvantly treated with bile acids. We also used 
another type of lithotriptor. 
We found that conventional cholecystectomy is superior to ESWL in terms of quality of 
life improvement. Only recently, a large panel of specialists from different disciplines 
declared that open cholecystectomy should still be judged the gold standard [2). In current 
medical practice, however, both treatment modalities have been surpassed bij laparoscopic 
cholecystectomy [15), although it must be noted that this new procedure has not been 
properly assessed in a randomized trial [9,16). Obviously, this development hampered patient 
accrual in our study. Only about a third of the originally planned n. mber of patients could 
be recruited and a subanalysis on initial stone load could not be performed due to the fact 
that the subgroups included too few patients. 
The general adoption of laparoscopic cholecystectomy probably leaves one of the most 
important conclusions of our study that the NHP is a useful tool for research in general 
surgery, even if numbers of patients are relatively small. In cases where laparoscopic 
cholecystectomy is not feasible, e.g. after previous upper abdominal surgery, open 
cholecystectomy is to be preferred to ESWL. However, in patients who are unfit or unwilling 
to undergo surgery, ESWL is an adequ~te form treatment because the majority of patients 
obviously benefit from it in terms of quality of life. 
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CHAPTER 7 
Cost-effectiveness of extracorporeal shock wave lithotripsy and cholecystectomy 
P.W. Plaisier, B.A. van Hout, H.G.T. Nijs 
75 
Abstract 
The possible acceptance of extracOIporeal shock wave lithotripsy (ESWL) as a serious 
treatment modality for symptomatic gallstones would not only have depended on its 
outcomes, but also on the accompanying costs. In this chapter, the results of several studies 
on the cost-effectiveness of ESWL are discussed. It is concluded that ESWL is not as cost-
effective as cholecystectomy. From an economic point of view, it is, therefore, unlikely that 
ESWL emerges as the treatment of choice for symptomatic gallstones. ESWL may only play 
a role for elderly individuals with solitary stones. 
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Introduction 
Evaluating the economic impact of medical procedures is of increasing importance in Western 
societies. This is especially true in the case of new technologies. Nowadays, the acceptance 
of any new treatment modality depends not only on its outcomes, but also on the 
accompanying costs. 
When the Rotterdam Gallstone (ROGAL) Study was started, a cost-effectiveness-analysis 
(CEA) was included. The results of this adjoined study are described in detail elsewhere [1]. 
m this chapter, the available reports regarding the cost-effectiveness of extracorporea1 shock 
wave lithotripsy (ESWL) will be discussed. 
Results from the ROGAL Study 
The CEA of the ROGAL Study was performed by the Institute for Medical Technology 
Assessment under the supervision of the Dutch National Health Insurance Council. In 1992, 
this council decided to stop frnancial support. First, because patient accrual was poor 
(Chapter 9). And second, because the determination of the economic value of ESWL had lost 
its relevanance after the universal adoption of laparoscopic cholecystectomy. The CEA was, 
therefore, stopped and a comparison of costs and effects was based on the then available 
data. 
costs 
Costs calculations were based on the data, collected in the period September 1989 - January 
1992. The data included 42 patients with a follow-up of 3-27 months. 
It was estimated that the mean factual costs for patients receiving ESWL were f3676 
(Table 1). A breakdown of the costs shows the relative importance of the costs of the 
interventions. Of these, the costs of the ESWL prooedures are highest (78%). Although an 
ESWL session costed only f1259, patients required an average of 2.13 sessions, resulting 
in 12681 per ESWL patient. The costs of pre- and posttreatment follow-up were primarily 
due to the regular ultrasonographic examinations (f648). Additional costs consisted of 
adjuvant bile acid therapy and hospitalization. Bile acid therapy costed f5.43 per day and 
were taken for an average duration of 1 year. The costs of hospitalization were caused by 
the fact that some patients eventually require cholecystectomy, although these costs did not 
have a substantial impact because the mean hospitalization time of ESWL patients was only 
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1.6 days. 
Table 1: mean costs per patient for extracorporeal shock wave lithotripsy (ESWL) and 
cholecystectomy (in Dutch guilders); in parentheses: costs as a percentage of the total 
ESWL Cholecystectomy 
Laboratory tests 139 (4) 216 (14) 
Radiological examinations 679 (18) 45 (3) 
Interventions 2858' (78) 1333' (84) 
Total 3676 1594 
1) including ESWL, electrocardiography, cholecystectomy and endoscopic retrograde cholangio-pancreatricography. 
2) including cholecystectomy and electrocardiography. 
The total mean costs (i.e. the mean factual costs and the mean additional costs) for 
ESWL were eventually estimated atf6700 (Figure 1). It should be noted, however, that this 
estimate did not include costs induced by eventual stone recurrence. This had not been 
observed. A more substantial follow-up, however, showed stone recurrence in 14% of the 
ESWL patients (Chapter 5). 
Mean factual costs per cholecystectomy patient were fl594 (Table 1). These costs were 
covered almost exclusively by the interventions. When the costs for hospitalization were 
added, the mean total costs for cholecystectomy was f4650 (Figure 1). There was no 
significant difference between the median hospitalization time of patients undergoing 
cholecystectomy in or outside the trial. This was checked in a series of all patients 
undergoing cholecystectomy (n=170) at the University Hospital 'Dijkzigt' in 1990. 
When comparing the course of the cumulated costs during treatment, there was a marked 
difference between the two treatment arms. The mean total costs of cholecystectomy were 
reached within two weeks, whereas the costs ofESWL rose steadily during the entire follow-
up (Figure 1). Indirect costs, such as those related to absence from work, were not calculated 
due. 
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Cumulative mean total costs per patient 
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Figure 1: cumulatiw costs per patient for extracorporeal shock wave lithotripsy (ESWL) and 
cholecystectomy 
In conclusion, ESWL is substantially more expensive than cholecystectomy in terms of 
direct medical costs. A major reduction in costs may be achieved if the average number of 
ESWL sessions can be reduced or if ESWL would be effective without adjuvant treatment 
with bile acids. 
effects 
For a detailed analysis of the effects of ESWL and cholecystectomy, the reader is referred 
to the Chapters 5 and 6 of this thesis. 
cost-effectiveness 
Considering that ESWL is more expensive in direct medical costs and has less pronounced 
effects than cholecystectomy, it is concluded that ESWL is not as cost-effective as 
cholecystectomy. 
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Discussion 
The first publications on the costs of ESWL calculated only in-hospital costs of ESWL in 
regard to cholecystectomy [2-4]. Actual CEA's ofESWL appeared later [5,6]. Reports were 
based on either computer models [5,6] or prospective findings [4,7]. 
Already the first study revealed that ESWL was accompanied by higher mean costs than 
cholecystectomy ($8100 vs. $6240) [2]. This conclusion was later confirmed by other studies 
[3-5,7], in which varied subsets of costs (e.g. for laboratory tests and professional) were used 
and ESWL was perfomed either as an outpatient [1,3,5] or an inpatient [2,4,7] procedure. 
Nealon and co-workers found approximately the same mean calculated costs for the 
ESWL-procedure as Rothschild ($8275) [3]. When the costs for bile acid therapy, screening 
and follow-up were added, the total costs were calculated as being $12,186. When patients 
who finally required Cholecystectomy or in whom lithotripsy failed were excluded from the 
denominator, the total costs of ESWL were eventually $15,087. 
A multispecialty panel from the John Hopkins University also found that the costs of 
ESWL outranged those of cholecystectomy [5]. Survival and quality-adjusted survival was 
better for ESWL than cholecystectomy, but this is rather obvious considering the marked 
difference in mortality. A subanalysis showed that ESWL became 10-20 times as cost-
effective in elderly patients. 
Also in the study of The Sheffield Group, the overall mean costs per patient of 
cholecystectomy were significantly less than for ESWL [7]. This was, however, more 
pronounced for large stone loads than small stone loads [7]. This result was also found in 
other studies [5,8]. 
There is only one report that concluded that ESWL should be the procedure of choice 
from society'S point of view [6]. Still, a major drawback of this study was that calculations 
were based on the stone clearance and complication rates, as published by the Munich Group 
[9]. Considering that these data have never been reproduced [3,10], the calculations may be 
regarded as too optimistic and clearly prepossessing ESWL. Another drawback was that it 
was assumed that common bile duct explorations occurred 25 % of the cholecystectomies. 
This percentage seems rather high and clearly disadvantages cholecystectomy for it has been 
shown that the complication and death rates of a cholecystectomy largely depend on whether 
it is accompanied by a common bile duct exploration [11]. A final drawback was that only 
calculations were made for patients under the age of 65 with solitary stones with a diameter 
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of :5 20 mm. It has been shown that these patients represent only about 10 % of the gallstone 
patient population [12]. 
In conclusion, all major reports agree that ESWL is accompanied by more costs than 
cholecystectomy. Most actual CEA's conclude that ESWL is, furthermore, less effective. 
Moreover it is likely that the one study that suggested that ESWL would be more cost-
effective, made the wrong assumptions. 
From an economic point of view, it is unlikely that ESWL will emerge as the tJeatment 
of choice for symptomatic gallstones. Preliminary cost-utility analyses on laparoscopic 
cholecystectomy indicate that it is even less expensive and more effective than open 
cholecystectomy [8,13,14]. ESWL may, therefore, only playa role for elderly individuals 
with solitary stones. 
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CHAPTER 8 
Radiographic features of oral cholecystograms of 448 symptomatic gaUstone patients: 
implications for nonsurgical therapy 
P.W. Plaisier, K. Brakel, R.L. van der Hul, H.A. Bruining 
Eur J Radiol (in press) 
83 
Abstract 
Because radiographic findings at oral cholecystography (OCG) have implications for the 
eligibility for nonsurgical therapy of elderly patients, we investigated the OCGs of 448' 
symptomatic gallstone patients (109 male, 339 female; mean age 49.8 ± 14 [range: 21-88]). 
Opacification of the gallbladder was found in 323 cases (72.1 %). Calcifications of gallstones 
were found in 85 opacified gallbladders (26.3%). Solitary and multiple stones were calcified 
in 35.3% and 18.2%, respectively [p<O.0005]. When divided into two groups (,;;40 years 
and >40 years), there was a significant increase in calcifications [p<0.02] and a non-
significant increase, in opacification with increasing age. It is concluded that age is a 
determinant for calcification of gallstones and not for opacification of the gallbladder. 
Because multiple stones are proportionately observed more in clinical studies than in 
epidemiologic studies, it is suggested that multiplicity of stones predisposes to biliary 
complaints. That solitary stones are more likely to be calcified than multiple stones, adds to 
the hypothesis that solitary and multiple stones have a different pathogenesis. Elderly 
patients, in whom nonsurgical therapy is most likely to be indicated and cost-effective, are 
less likely to be suitable for this form of treatment, because age is a determinant for stone 
calcification. 
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Introduction 
The development of oral cholecystography (OCG) is one of the milestones in the history of 
roentgenology [I). It has been the unchallenged standard in the diagnosis of gallbladder 
disease for half a century. but less than five years after the introduction of ultrasonography 
(US). OCG disappeared almost entirely from clinical practice. The introduction of several 
nonsurgical treatment modalities for gallstone disease [2-8), resurrected the use of OCG for 
it can provide information on stone composition and patency of the cystic duct. 
We analyzed the OCGs of 448 symptomatic gallstone patients for their radiographic 
features. The aim of this study was twofold. First, we wanted to investigate if age is a 
determinant of calcification of gallstones and nonopacification of the gallbladder, because this 
would have implications for the eligibility for nonsurgical therapy of elderly patients. Second. 
we wanted to investigate to what extent our clinical findings agreed with epidemiologic 
findings. This paper reports our findings. 
Patients and methods 
In 1988 a surgical outpatient biliary clinic was started. It was especially designed to select 
patients for alternative treatment modalities for gallstone disease, such as orally administered 
bile acids [2,3), contact dissolution [4,5), extracorporeal shock wave lithotripsy (ESWL) 
[6,7) and rotary contact lithotripsy [8). 
In the period April 1988 - April 1992, 774 patients visited this clinic. All patients were 
analyzed according to protocol: patient's history, physical exantination and -if patients were 
considered symptomatic- laboratory tests and radiologic examination. Patients were 
considered symptomatic only, if they had experienced one or more episodes of abdominal 
pain (usually epigastric or right upper quadrant) lasting more than 15 min but less than 5 h, 
according to the Roma Working Team definition [9). 
Radiologic examination consisted of US and OCG. Calcifications were only recorded in 
visualized gallbladders, analogously to the GREPCO- study [10). Results of recent 
examinations done elsewhere, were not repeated and used in this study. An OCG was not 
performed, when the patient refused a nonsurgical therapeutic option or if previous US 
examination excluded the patient by our ESWL entry criteria (> 10 stones, stones with a 
diameter < 5mm, common bile duct stones, aneurysms or cysts in the shock wave path and 
pregnancy) [7]. 
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One-hundred and thirteen patients (14.6%) were excluded from OCG, because they had 
no biliary symptoms. Of the 661 symptomatic patients, 213 patients (32.2 %) had no OCG 
performed because they preferred cholecystectomy. OCG was performed after intake of 
iocematic acid (Cholebrine,) the evening before the examination. Intake of Cholebrinef 
[iocematic acid] was according to body weight: < 60kg : 3.00g [1.86g]; 60-90kg : 4.50g 
[2.79g]; >90kg : 6.00g [3.72g]. Cholebrine' was taken orally in two steps with an interval 
of one hOUf, with some water, after which the patient was not allowed to eat, drink or 
smoke. Intake was planned in such away, that fasting time was approximately 12 h. 
Due to logistical reasons we were not able to provide repeat doses in the case of 
nonvisualization of the gallbladder. However, it has been demonstrated that in patients in 
whom normal opacification occurs after a repeat dose, the initial dose already gave a faint 
visualization of the gallbladder [II]. Therefore, we categorized faint visualization as 
opacification being present. 
All data were recorded on standardized forms by the performing radiologists, without 
knowledge of previous examinations. On these standardized forms used for OCG the 
radiologist recorded whether there was opacification (yes/no), the number of gallstones (0, 
1,2,3,4,5,6-10, > 10), the diameter of the largest stone (in mm), whether the stones were 
calcificied (yes/no) and if there was buoyancy [the presence of floating stones] (yes/no). In 
addition, if present, the sort of calcification (core, rim <2mm, rim>2mm, total) was 
recorded. Finally, in the case the gallbladder did not opacificy, whether there was contrast 
in the small bowels (yes/no) to determine the patient's compliance. In the case of 
nonspherical stones the largest diameter was recorded. Measurements of stone size was 
corrected for an empirically determined magnification factor of 1.3. 
Statistical analysis was done by means of regression analysis, the Chi-square test for 
trends in proportions, and the test for differences between proportions assuming binomial 
distributions. 
Results 
Four hundred and forty eight patients (109 male, 339 female; mean age 49.8 ± 14 [range: 
21-88]) underwent OCG. Opacification was found in 323 cases (72.1 %) and nonvisualization 
in 125 (27.9 %). Calcifications were found in 85 cases of 323 visual;zed gallbladders 
(26.3 %). These results are summarized in Table I together with the calcification patterns. 
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Table J: ga1lbladder opacification, stone calcification and buoyancy recorded at oral cholecystography 
in 448 symptomatic gallstone patients 
Feature No. of patients Percentage 
Gallbladder 
-opacification 323 72.1 
Gallstones 
-calcification 85 26.3 
completely 30 35.3 
rim ~2mm 24 28.2 
rim >2mm 13 15.3 
core 13 15.3 
not recorded l 5 5.9 
-buoyancy 20 4.5 
1) OCG perfonned in another ho~pital 
Between the sexes there was no significant difference in opacification (69.7% [males] vs. 
74.6% [females]; p=O.3I) and calcifications (31.6% [males] vs. 24.1 % [females]; p=0.19). 
Stones were calcified in 35.3% of the solitary stones [36/102] and in 18.2% of multiple 
stones [49/269] (p<0.0005). Mean diameter of the largest stone was on OCG 17.3 ± llmm 
[range: 3-65]; median=15mm. 
The distribution of number of stones is depicted in Table 2. With US, solitary stones 
were found in 30.1 % of all 448 cases and 33.1 % of the 323 gallbladders, visualising at 
OCG. Mean diameter of the largest stone measured with US, was 14.2 ± 8mm [range: 3-
45]; median=12mm. 
Patients ,,;:40 yrs and >40 yrs had opacified gallbladders in 69.3% [88/127] and 73.2% 
[235/321] of the cases, respectively (p=0.40). Patients ,,;:40 yrs and >40 yrs had calcified 
stones in opacified gallbladders in 16.9% [15/89] and 29.9% [70/234] of the cases, 
respectively (p<0.02). 
Discussion 
US is the preferred diagnostic tool for detecting gallstones, for it is noninvasive and -unlike 
OCG- simple to perform, lacks ionising radiation and is independent of hepatic function 
[12,13]. Moreover, US is slightly more sensitive than OCG [14] (Table 2). Still, OCG is 
very reliable in determining gallstone size and number [14]. It also provides information 
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Table 2: distribution of number of stones at oral cholecystography (OCG) and the corresponding 
findings at ultra~mography (US) in 323 visualized gallbladders of 448 symptomatic patients 
Number of stones Number of patients on OCG (%) Number of patients on US (%) 
0 54 [16.7] 18 [5.6]' 
102 [31.6] 107 [33.1] 
2 41 [12.7] 41 [12.7] 
3 13 [ 4.0] 20 [6.2] 
4 12 [ 3.7] 11 [ 3.4] 
5 8 [ 2.5] 23 [ 7.1] 
6-10 24 [ 7.4] 27 [ 8.4] 
> 10 57 [17.6] 65 [20.1] 
Not specifically stated 12 [ 3.7] II [ 3.4] 
Total 323 323 
1) grit (concrction~ <3mm) [6J. polyp~ [4J, ~Iudgc [2J, adcnomyomato~is [IJ, passsed :nones [5J. 
on the' functional state of the gallbladder, information which is necessary for several 
nohsu,rgical treatment modalities for symptomatic galJstones. 
We analyzed the radiographic findings of 448 symptomatic gallstone patients. It is one 
of the largest prospective clinical studies available in the US era. Moreover, these data were 
double-checked with US in all cases. That different radiologists interpreted the DCas most 
probably did not influence results, because it has been demonstrated that there is little inter-
observer variety in assessment of visualization of the gallbladder and opaqueness of gallstones 
[10]. 
We found an overall opacification rate of 72.1 %, which is comparable with two 
epidemiologic studies in Italy [10, IS]. Although:Mujahed et al. found an overall visualization 
rate of 91.7%, it must be borne in mind that he used a different DCa regimen [16]: at day 
I of his 2-day examination, 75.2% of the gallbladders opacified which is indeed comparable 
with our data. We also found that age is not a determinant of visualization, which was also 
found by the Rome group [10]. 
We demonstrated an overall calcification rate of 26.3%, a percentage also largely 
comparable with the Rome group, which found radiopacity in 29.1 % of the cases [10]. It is 
also in accordance with the clinical impression that radiolucent prevail over radiopaque stones 
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[17]. We found that elderly are more likely to have calcified gallstones than younger patients, 
which is in accordance with Bell's chemical analysis of gallstones [18]. However, unlike Bell 
and others [19], we, like the GREPCO-study, were not able to demonstrate a significant 
larger calcification rate in men than in women. This is most probably caused by the fact that 
radiologic studies do not entirely reflect the chemical structure of the gallstones, because not 
all calcifications are shown at radiography [20]. On the other hand, the discrepancy may be 
due to selection. Bell found a radiopaqueness in 50% of patients coming to cholecystectomy 
and in his manuscript he already noted that this rate was considerably higher than reported 
elsewhere [18]. He argued that radiopaque stones were more likely to be detected than 
radiolucent stones, which was true because his study was performed in the pre-US era. Sutor 
and Wooley also used gallstones removed at cholecystectomy [19], possibly explaining the 
difference. 
We have found that multiple stones prevail over solitary stones with both OCG and US, 
which is in accordance with the clinical impression [17]. This was also found in a another 
clinical study performed by Brink, who investigated the contents of extirpated gallbladders 
[21]. Epidemiologic studies, however, demonstrate solitary stones in 40.5-50.9% of the 
OCGs [10,22] and 45% of the USs [23]. This discrepancy between clinical and epidemiologic 
studies suggests that multiple stones are more likely to cause biliary symptoms than solitary 
stones. This impression is in accordance with the findings of the National Cooperative 
Gallstone Study, where patients with multiple stones had more biliary pain before entering 
the study and were more likely to develop symptoms during the prospective follow-up [24]. 
Finally, to our knowledge, we are.the first to report on the finding that solitary stones 
are calcified more often than multiple stones, which fmding adds to the hypothesis that 
solitary and multiple stones have different etiologies [25]. 
Our fmding that elderly patients are more likely to have calcified gallstones imply that 
these patients are less likely to profit from nonsurgical therapy. First, because all sorts of 
calcifications exclude the!11 from oral and contact dissolution therapy [2-5]. Second, because 
calcifications of >2mm are contraindicated for ESWL [6,7]. And third, because stones with 
a calcified rim :52mm are even less likely to be cleared with ESWL than noncalcified stones 
[26]. In contrast to this, is the fact that rotary contact lithotripsy is able to treat all sorts of 
stones, including calcified ones [8]. This form of treatment, however, is invasive and not 
readily available in most clinics [27]. 
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That elderly patients are less likely to be suitable for nonsurgical therapy is regrettable, 
because in these patients this form of treatment is most likely to be indicated and cost-
effective [28]. 
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CHAPTER 9 
Unexpected difficulties in randomizing patients into a surgical trial: experiences from 
a prospective study comparing extracorporeal shock wave lithotripsy with open 
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Abstract 
Shortly after extracorporeal shock wave lithotripsy (ESWL) was introduced as a promising 
new treatment modality for gallstone disease, a randomized controlled study was performed 
to assess the (cost-) effectiveness of ESWL, compared to open cholecystectomy, the gold 
st.ndard. During the performance of this study it was found that in a 3-years intake period, 
only 8.3% (37/448) of the patients could be entered into the trial. Three factors could be 
identified, which hampered patient accrual. First, restricted eligibility for ESWL (and thus 
for the study), which could not have been predicted on the data provided in the literature. 
Second, the introduction oflaparoscopic cholecystectomy. Third, strong patient's preference, 
inhibiting randomization. All three mechanisms could not have been predicted during the 
design phase of the study. It is concluded that it is not always feasible to conduct a 
randomized study In surgery due to unforseen circumst.nces. Entering patients Into surgical 
trials is difficult in quickly evolving fields of surgery, such as the management of gallstone 
disease. Acquiring informed consent is also difficult when treatment characteristics are very 
divergent. A good randomized controlled study on the effects of laparoscopic 
cholecystectomy will, therefore, most probably never be performed. 
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Introduction 
Gallstone disease is an important clinical problem in western countries and traditionally 
considered a surgical problem. It is generally agreed that open cholecystectomy is the 
standard therapy for symptomatic gallstones [1,2]. Still, much effort is put into the 
development of alternative, preferably non-invasive, treatment modalities for gallstone disease 
[3]. One of these recently developped, non-invasive, treatment modalities for gallstone 
disease, is extracorporeal shock wave lithotripsy (ESWL). The initial results of ESWL of 
gallbladder stones were very promising [3-5]. 
Because of the possibly tremendous clinical and economical consequences of ESWL, we 
initiated a study on the effects of this new technique and its cost-effectiveness [6]. We choose 
a randomized controlled design, since randomized studies are considered to provide the most 
reliable information for proper evaluation of new techniques [7-14]. Moreover, in this way, 
discussions could be avoided, similar to the ones that developed after the general adoption 
of ESWL of kidney stones: this treatment modality almost completely displaced open surgery 
although a randomized study never was performed [15-17]. 
During the performance of our study, several problems were encountered in acquiring 
adequate patient accrual. In this paper we describe the difficulties we met in patients' accrual. 
Patients and methods 
To assure optimal patient accrual for our randomized study, a surgical outpatient clinic solely 
for gallstone patients was started. In a 3-year intake period, 596 patients visited this 
outpatient clinic. 
All patients were analyzed according to protocol: of all patients a history was taken and 
a physical examination performed. Using the Roma Working group definition [18], patients 
were diagnosed as either ' symptomatic' or • a-symptomatic'. Asymptomatic patients were 
excluded from further analysis and did not receive therapy. With symptomatic patients the 
different therapeutic options were discussed. These patients underwent further analysis: 
laboratory tests and radiological examination. 
Laboratory tests consisted of liver function tests for screening on common bile duct 
stones and radiological examination consisted of ultrasonography (US) and oral 
cholecystography (OCG). An OCG was not performed, if the patient refused ESWL as a 
therapeutic option or if a previous US examination already excluded the patient from ESWL 
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(Chapter 4; Table I). 
At the end of analysis, all eligible patients, were informed about the study and asked for 
consent to be randomized. When informed consent was given, therapy was randomly 
assigned and self-administered health questionnaires and interviews were taken at 0,3, 6, 12, 
18 and 24 months. If patients did not want to participate in the study, they received the 
therapy of their choice. 
Results 
From April 1989-April 1992, 596 (successively: 238, 179 and 179) patients visited the 
outpatient clinic. Their characteristics are presented in Table I. Three hundred and sixty 
seven patients (61.6%) were referred by their general practioner, 141 (23.7%) by specialists 
and 88 (14.8%) visited on their own initiative. Five hundred and eighty four patients (98.0%) 
underwent US and 345 (57.9%) OCG. 
Table 1: patient characteristics in 596 patients referred to the University Hospital 'Dijkzigt' for 
gallstone management 
age 
range 
oN-ratio 
Q-index' > 27.0 
ASA'lII/IV 
symptomatic 
total 
\) Q-index : Quetelet index: weight [kg]/(length {m]): 
49.1 ± 14.5 
19 - 88 
0.36 [158/438] 
175/498 [35.1%] 
19 [ 3.2%] 
499 [83.7%] 
596 
2)ASA : c1assificntion of anaesthesia risk according to the American Society of Anae~thesiologists 
Twelve patients discontinued analysis and 96 patients were not symptomatic (Figure 1). 
Of 488 patients, potentially randomizable, 310 (69.2%) were excluded because they did not 
meet the entry criteria. Another 141 patients (31.5%) were excluded because they refused 
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random assignment of therapy. So, 37 patients (18, 12 and 7, respectively) consented in 
entering the study, which is 6.2 % of the total number of analyzed patients and 7.6% of the 
patients potentially randomizable. Eighteen patients were randomized for cholecystctomy and 
19 for ESWL. 
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Figure 1: flow chart for not entering the study 
1) cholccy~'1itill. jaundice, cholangitis. pancreatitis. hcpatiti~ or concomitant bile duct stonc~ 
2) US '" ultrasonography 
3) OCG = 01'11,1 cholecystography 
4) ESWL '" ExtracorporeaJ Shock Wave LithOtriPllY 
5) 8.3 % of 488 potentinlly randomiznblc patients 
Discussion 
There is unanimous agreement that new treatment techrtiques should be introduced in a 
manner that allows proper evaluation [7]. Although randomized studies have specific 
problems, they are considered to provi!'ie the most reliable information for such evaluation 
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[7-14,19]. The mechanism of allocating patients to different treatment schemes by 
randomisation, is accepted almost without question now [10], 
New surgical techniques are considered more difficult to evaluate than new drugs [16,20], 
In fact, most clinical research in surgery. relies on comparison with historical or 
contemporary non-random controls [II]. One of the most striking examples of this 
phenomenon, is ESWL of renal and ureteric calculi, which completely displaced open 
surgery [15]. This development consequently led to much discussion, since no randomized 
study was ever performed [16,17]. When ESWL was introduced for the desintegration of 
gallbladder stones, it was therefore suggested that the proper assessment of the role of ESWL 
should be delt with in the context of a randomized trial [3]. 
During the performance of our study, only a minority of patients could be randomized. 
It should be noted here, that despite this poor patient entry, it was decided to continue the 
study. First, because interim-analysis showed some interesting points. Second, because five 
other hospitals decided to participate in the study. Third, because a large number of non-
randomized patients were entered into the study. However, since this is besides the point of 
this manuscript, this is not discussed here. 
Poor patient entry was caused by three mechanisms, which could not have been predicted 
when the study was designed. First, contrary to the data in the literature, eligibility for 
ESWL was found to be limited. Second, yet another alternative treatment of gallbladder 
stones was introduced during the performance of our study. Third, strong patient preference 
for one of the two treatment arms was encountered, which inhibited randomization. 
Restricted eligibility for ESWL 
Partial applicability was reported already by Sackmann and co-workers [4]. However, this 
was not considered a major obstacle for our study, for we had reasons to assume that our 
eligibility rate would be higher than that reported by the Munich group. First, because our 
entry criteria were much wider than those of the Munich group, especially with regard to the 
maximum number of stones (10 versus 3). Second, because another research group reported 
a randomisation rate of 57.1 % in a trial comparable to ours [21]. Moreover, even at 
Sackmann's eligibility rate of 28%, accrual of 160 patients -estimated to be necessary to 
detect any clinically relevant differences in the two treatment options- was considered to be 
easily achieved in 3 years at our referral rate of approximately 200 patients per year. 
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The introduction of yet another alternative treatment 
Shortly after our study was started, a new variant of classical cholecystectomy was 
introduced: laparoscopic cholecystectomy [22,23]. Compared to the 'open' technique, 
laparoscopic cholecystectomy is reported to have several advantages. It is accompanied by 
less morbidity and mortality and consequently by a reduction in duration of hospitalization. 
time to return to full activity and the need for analgetic drugs. Also for cosmetic reasons, 
laparoscopic cholecystectomy is more attractive. Laparoscopic cholecystectomy is considered 
the new gold standard now [24] even although this technique has not been studied in the 
context of a randomized trial. 
Strong patient's preference 
Many mechanisms may lead to strong patient's preference. Two mechanisms limited accrual 
in our case: adherence to new technologies and the divergent character of the two treatment 
arms. The lay press most probably reinforced these two mechanisms. 
Adherence to new technologies 
Emotional adherence to new technologies is considered a major obstacle for randomisation 
and it even becomes insurmountable if it has spread to the general public [13]. We even 
encountered this phenomenon twice: in the beginning of the study when patients specifically 
chose ESWL and in a later stage of our trial when patients specifically opted for the 
laparoscopic cholecystectomy. 
The divergem character of the two treatmem arms 
Strong patient's preference also occurs when the treatment modalities studied are very 
divergent [25,26]. ESWL and cholecystectomy have indeed very different characteristics 
(Table 2) and since the outcomes of these characteristics were so clear to many patients, they 
specifically opted for a certain treatment modality and simply rejected random assignment. 
It has been recognized before that comparing treatment regimes with divergent characteristics 
is extremely difficult [27]: only 2% of eligible patients are recruited in breast cancer trials 
in the United States (28) and in a trial comparing mastectomy and conservation surgery in 
Great Britain, fewer than half of the eligible patients could be recruited [29]. Recently, some 
of the large trials comparing percutaneous transluminal coronary angioplasty (PTCA) and 
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coronary artery bypass graft (CBAG) have also stopped intake without having recruited the 
aimed number of patients [30]. 
Table 2: base line characteristics between cholecystectomy and extracorporeal shock wave lithotripsy 
(ESWL) 
Cholecystectomy 
outpatient procedure 
general anaesthesia 
curative 
probability on stone recurrence 
biliary colics after initial therapy 
morbidity 
mortality 
adjuvant treatmentl required 
1) orally administen::d bile acid~. 
+ 
+ 
0% 
10-30% 
0.1-0.3% 
ESWL 
+ 
+ 
35% 
<5% 
0% 
+ 
In the field of gallstone management, a trial comparing laparoscopic cholecystectomy and 
the so-called 'mini-cholecystectomy' suffered from a high withdrawel rate after randomisation 
and this trial was eventually stopped because of difficult patient recruitment [31]. The only 
alternative to overcome this particular problem clearly would have been to randomize patients 
without their informed consent, analogously to the European Carotid Surgery Trial [32]. 
The role of lay press 
The role of lay press in hampering patient accrual has been recognized before [29]. Also in 
our study, lay press played an important role in promoting patient's preference: in some 
popular magazines successes of ESWL and laparoscopic cholecystectomy were extremely 
exaggerated and the possibility of faillure and complications underestimated or not mentioned 
at all. Obviously, this promoted patient's preference to a large extent. As a consequence, the 
universal adoption of laparoscopic cholecystectomy has been merely patient driven [33,34], 
as a result of media exposure [35]. 
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Conclusions 
Our data confirm that proper information on the feasibility of a trial is not always available 
before it is started [35]. Our data also confirm that it is not always feasible to conduct a 
randomized study successfully because of inadequate patient accrual [9]. Furthermore, we 
confirmed that acquiring informed consent is much more difficult if treatment characteristics 
are very divergent and that comparing different forms of therapy in a randomized studies is 
hazardous in quickly evolving fields of surgery, such as the management of gallstone disease. 
It is, therefore, equally true that a prospective controlled study on the effects of laparoscopic 
cholecystectomy cannot be performed [7,36]. In such cases alternatives to randomized studies 
have to be used [8,13,26,37]. 
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CHAPTER 10 
Quality of life and the course of biliary and gastrointestinal symptoms after Iaparoscopic 
and conventional cholecystectomy 
P.W. Plaisier, R.L. van der Hul, H.G.T. Nijs, R. den Toom, O.T. Terpstra, H.A. Bruining 
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Abstract 
A prospective study was perfonned to evaluate quality of life and the course of biliary and 
gastrointestinal symptoms after laparoscopic cholecystectomy (LC) and conventional 
cholecystectomy (CC) for uncomplicated, symptomatic biliary disease. Fourteen patients 
underwent LC and 17 patients underwent CC. Quality of life questionnaires and symptom 
profiles were taken before and at 3, 6, 12, 18 and 24 months after therapy. Pain diaries 
covered the periods 0-3, 3-6, 6-12 and 12-18 months. Median follow-up was 12 and 24 
months for LC and CC, respectively. Quality of life significantly improved after 6 months 
in the LC-group and to a similar degree after 12 months in the CC-group. Stomach swelling, 
fatty food upset and nausea improved significantly at 3, 6 and 6 months after LC and at 6, 
18 and 24 months after CC, respectively. Vomiting and belching had a tendency to improve 
slightly, while pyrosis, constipation and diarrhoea did not improve in both groups. Biliary 
pain was cured in 81 % of the patients (25/31) directly after cholecystectomy. Biliary pain 
was not reported after 6 months after treatment. ChOlecystectomy improves quality of life 
and cures nausea, fatty food upset, stomach swelling and biliary pain. LC improves quality 
of life and symptomatology to the same degree in an earlier stage than CC. Therefore, with 
respect to quality of life and abdominal symptoms, LC is preferable to CC for the treatment 
of uncomplicated symptomatic gallstones. 
104 
Introduction 
Any form of elective surgery is directed primarily to improvement of quality of life, i.e. the 
relief of disability, discomfort and disfigurement [1,2]. Especially in the treatment of 
symptomatic gallstones, improving the patient's quality of life should be the most important 
aim of intervention [3]. We studied the effects of cholecystectomy on quality of life. We 
also studied its effects on the course of biliary and gastrointestinal symptoms. Finally, we 
studied differences between the effects of laparoscopic cholecystectomy as compared to 
conventional cholecystectomy, the gold standard [4,5]. 
Patiends and methods 
Thirty one patients with uncomplicated, symptomatic biliary stone disease were recruited 
from a surgical outpatient biliary clinic, in the period January 1990 - January 1993. Patients 
were diagnosed as 'symptomatic' according to the Roma Working Team-definition [6]. With 
this definition, symptomatic stone disease is characterized by acute biliary pain involving one 
or more episodes of abdominal pain (usually epigastric or right upper quadrant) lasting more 
than 15 minutes but less than five hours. The absence of biliary complications was 
demonstrated by physical examination, a white blood cell count, liver function tests and 
ultrasonography of the abdomen. 
laparoscopic cholecystectomy (LC) 
Fourteen patients, I man and 13 women, underwent LC. Mean age was 45 years (range 30-
68). Median Quetelet-index was 24.8 kg(m' (range 20.5-38.1). LC was performed via four 
abdominal incisions after insufflation of carbon dioXlde. It was performed under general 
anesthesia, as an inpatient procedure. Intra-operative cholangiography was not performed. 
Conventional cholecystectomy (ee) 
Seventeen patients, 3 men and 14 women, underwent CC. Mean age was 49 years (range 30-
67). Median Quetelet-index was 24.5 kglm2 (range 19.5-38.1). CC was performed by 
laparotomy, via an oblique subcostal incision. It was performed under general anesthesia, as 
an inpatient procedure. Intra-operative cholangiography was not performed. 
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Follow-up 
Follow-up consisted of self-administered health questionnaires, symptom profiles and pain 
diaries. A Dutch translation of the Nottingham Health Profile was used for the quality of life 
assessment [7]. This health profile questionnaire consists of 6 so-called domains, being 
explored in 38 questions requiring a 'yes' or 'no' answer (dichotomous). If all questions are 
answered 'yes', the patient scores highest, but is considered having the least quality of life. 
'Health gain' can be defined as the decrease in median score (ergo: the median decrease in 
positively answered questions). On the symptom profiles, the patients had to score whether 
they suffered from the following gastrointestinal complaints: nausea, fatty food upset, 
vomiting, stomach swelling, pyrosis, belching, constipation and diarrhea. Scoring was 
performed on a semi-quantative scale (absent, mild, moderate or severe). On the self-
administered 'pain diaries', patients had to fill out the date, the duration and severity (mild, 
moderate or severe) of pain, when experiencing biliary pain. Patients experiencing pain had 
to indicate specifically whether this pain was similar or different from the pain they 
experienced before cholecystectomy. Health questionnaires and symptom profiles were taken 
before therapy (t=O) and at 3, 6, 12, 18 and 24 months after therapy. Pain diaries covered 
only the post-operative phase, i.e. 0-3, 3-6, 6-12 and 12-18 months. Health questionnaires, 
symptom profiles and pain diaries were sent by mail and double-checked by telephone 1 
month after receipt. 
Statistics 
Statistical analysis was done with the Kruskal-Wallis test, Wilcoxon rank test and a standard 
test for comparing proportions assuming binomial distributions. A p-value of <0.05 was 
considered statistically significant. 
Results 
Laparoscopic cholecystectomy 
Mean and median hospitalization time, including the days of admission and discharge, were 
5 days (range: 4-9). No LC was converted into CC. Postoperatively, no complications 
occurred and there was no mortality. Mean follow-up was 13.1 months (median: 12; range: 
3-24). No patient was lost to follow-up. 
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Conventional cholecystectomy 
Mean and median hospitalization time, including the days of admission and discharge, were 
9 days (range: 6-12). Postoperatively, one patient had to be observed for 6 hours at an 
intensive care unit for an epileptic insult. One patient suffered from wound dehiscence, 
treated conservatively. Two patients complained of persistent scar pain. There was no 
mortality. Mean follow-up was 23.6 months (median: 24; range: 18-24). No patient was 
lost to follow-up. 
Ouality of life 
NHP-questionnaires were returned and filled out correctly in 96.5% (1651171) of the cases. 
It was found that the median overall percentage of items answered positively, decreased to 
the same degree in both treatment groups after therapy (Figure I). This decrease, however, 
became significant 6 months after LC and and only 12 months after CC. Health status 
remained Significantly better hereafter in both groups (not shown). There was no significant 
difference at baseline between the two treatment groups. 
HEALTH GAIN AFTER CHOLECYSTECTOMY 
Differences in median score 
16
1 m~_n"1 
:: r .. I'-~I 
10 f 1--1 I ' I 
:1 Iii \ 
tlLJJ-:.-_ ... __.~lJLj 
LC 0-3 LC 0-6 LC 0-12 CC 0-3 CC 0-6 CC 0-12 
Treatment 
Figure 1: median total scores (in %) on Nottingham Health Profiles after; on the abscissa: 
months 
LC: lapaooscopic cholecystectomy: CC: conventional cholecystcctomy;·"" p<O.OS; compared with 1""0 
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Gastrointestinal symptoms 
The reported frequencies of nausea, fatty food upset and stomach swelling in the course of 
I year, are depicted in Table I, Both fatty food upset and nausea improved significantly and 
consistently after 6 months in the LC-group but not in the CC-group. Here, a significant 
improvement in fatty food upset and nausea occurred only after 18 and 24 months, 
respectively (not shown). Stomach swelling improved significantly after 3 and 6 months in 
the LC and CC-group, respectively. Vomiting and belching improved only slightly in both 
treatment groups, but improvements were statistically insignificant. Reported frequencies of 
pyrosis, constipation and diarrhea did not change after therapy. There were no significant 
differences in reported symptoms between the two treatment arms at baseline. 
Table 1: reported frequencies (in %), graded moderate or severe, of fatty food upset, nausea and 
stomach sweIJing after laparoscopic (n= 14) and conventional cholecystectomy (n; 17) 
time 
(months) 
o 
3 
6 
12 
fatty food 
upset 
LC CC 
47 37 
33 21 
Ob 33 
Ob 16 
nausea 
LC 
47 
8" 
Ob 
Ob 
LC "" Laparocopie cholecy~'tectomy: CC = cOl)vel)tional cholecystectomy 
a) p<0.05; compared with t=O; b) p<O.02: compared with t=O 
BiJiairy pain 
stomach 
swelling 
CC LC CC 
37 33 47 
16 Ob 32 
17 10 11" 
26 Ob 11 b 
Post-cholecystectomy biliary pain was found in 5 patients in the CC-group (29%) and I 
patient (7%) in the LC-group. This difference was not statistically significant (p=0.12) In 
the CC-group, 4 patients complained of 2-4 and I patient of 11 pain episodes, respectively. 
The LC-patient reported only I episode. Pain episodes were considered mild, moderate or 
severe in 29, 48 and 24%, respectively. No biliary pain was reported after 6 months after 
cholecystectomy. 
108 
Discussion 
LC has revolutionized clinical practice to a great extent and it has been claimed already that 
LC is the new gold standard for symptomatic gallstone disease [8]. However, well-controlled 
studies are unavailable [5] and there is little or no prospect that good randomized studies will 
ever be performed [9]. The one available randomized study was hampered by a significant 
age difference between the two studied groups [10]. 
The few available controlled studies all have some drawbacks. First, they usually used 
historic controls [11-13]. Second, they emphasized on complications and mortality [12,13]. 
Because both LC and CC are accompanied by relatively low morbidity and mortality rates, 
these rates are insensitive and, therefore, inappropriate to detect any differences between the 
two treatment arms in small series of patients [1,14,15]. Third, they also focused on 
operative time, hospitalization time and use of analgesia [11], which is only partially of 
interest to the patient. 
We studied LC prospectively as compared to CC, which has been the standard operation 
for gallstone disease for more than a century [4]. We emphasized on quality of life, because 
this seems to be of major interest to the patient. Moreover, especially ntinimally invasive 
surgery is an area well suited for quality-of-life research [15] and in fact, improving quality 
of life is always the most important aim in the elective treatment of symptomatic gallstones 
[3]. 
We chose the Nottingham Health Profile, since it is well validated and one of the most 
widely used general measures of quality oflife [14]. Moreover, it can be easily adntinistered 
by mail and makes relatively small demands on patient time and effort [14-16]. Because there 
was a significant difference in follow up between the two treatment groups (p=0.03), we 
analyzed only the data of I year in the LC-group. 
We found that both therapies are safe, cure biliary colics and improve both quality oflife 
and three gastrointestinal complaints, i.e. fatty food upset, nausea and stomach swelling. 
These data are in accordance with data recently published in a larger series of patients [17]. 
We also found that symptoms may persist after cholecystectomy, which is in agreement with 
the literature [18-21]. Because of the specific design of the pain diaries and symptom 
questionnaires, we could confirm that the reported symptoms were usually mild and of short 
duration [18-21]. We, therefore, reconfirmed that cholecystectomy is justified as a treatment 
of uncomplicated symptomatic gallstone disease. 
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Compared with CC, we demonstrated that LC improves quality of life significantly 
earlier. This was also the case with fatty food upset, nausea and stomach swelling. Finally, 
we confirmed that LC caused a marked reduction in hospitalization time. 
Drawback of our study is that it was not randomized and that the number of studied 
patients is relatively limited. Our study could not be designed as a randomized study, because 
it was initiated in a phase where we could not constantly dispose of a laparoscopic set. 
Consequently laparoscopy could not be planned and in fact it was unpredictable what 
treatment hospitalized patients would get. Still, we doubt whether randomization would have 
been possible: when a laparoscopic set were constantly available, patients would simply 
refuse random assignment of treatment and chose LC, Despite this, the present study was 
prospective, controlled and has a relatively long follow up. We could, therefore, provide 
more circumstantial evidence that LC is superior to CC. 
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CHAPTER 11 
Current role of extracorporeal shockwave therapy in surgery 
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Abstract 
In urology the introduction of extracorporeal shockwave therapy brought a revolutionary 
change in the management of urinary calculi. This inspired the introduction of shockwave 
therapy in several fields of surgery; it has been applied as a potential alternative to several 
operative procedures, but is still experimental. So far, the major application of shockwave 
therapy has been lithotripsy of stones in the gallbladder, common bile duct, pancreatic duct 
and salivary gland ducts. Other applications are in the non-operative management of bone 
healing disturbances and in the inhibition of tumour growth. Steps towards selective thrombus 
ablation and pretreatment of heavily calcified arteries, have also been made. In this review, 
the applications of extracorporeal shockwave therapy in several areas of surgery are 
discussed. It is concluded that, for selected patients, shockwave therapy may serve as a 
useful addition to the surgical armamentarium. 
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Introduction 
In 1980 the first clinical experience with extracorporea1 shockwave therapy for the treatment 
of kidney stones was reported [I]. Nowadays, it is the therapy of choice in the case of 
urolithiasis and surgical treatment is restricted to fewer than 5 per cent of patients [2]. After 
good results in urology, shockwave therapy has been applied to other calculi, such as stones 
in the gallbladder, common bile duct (CBD), pancreatic duct, and salivary gland. Other 
applications are currently being tested. In this paper the current role of shockwave therapy 
in surgery is discussed; shockwave therapy treatment of stones is referred to throughout as 
lithotripsy. 
Technical aspects and principles 
Shockwaves can be generated by three methods: underwater electrostatic spark-gap discharge, 
electromagnetic generation and piezo-electric generation [3,4]. Approximately 20 different 
shockwave therapy devices are currently available and the initial water immersion bath has 
been largely replaced by a compressible water bag. 
Shockwaves are characterized by their ultrashort high-pressure amplitudes with a steep 
onset and gradual decay; they obey the physical laws of acoustics. Shockwaves are generated 
in water and may travel through the human body without causing tissue damage, because 
both water and body tissue have a similar acoustic impedance. However, when such waves 
encounter an abrupt change of acoustic impedance, for instance at the interface of body tissue 
and a stone, energy is released. This causes tear and shear forces which, together with the 
formation of cavitation bubbles on the surface of a calculus, finally lead to progressive stone 
disintegration [5,6]. 
Objective comparisons of the working capacity of the different machines are considered 
difficult and are consequenlt1y rarely performed and contradictory [7-10). To date the 
lithotriptors available can achieve disintegration of stones in vitro to a similar degree, which 
is independent of their method of shockwave production [7,8] and similar results are expected 
in clinical use [7]. However, while electromagnetic and piezoelectric devices have higher 
retreatment rates than electrohydraulic systems [11], the former have lower complication 
rates and allow lithotripsy sessions to be less painful [8,11]. Generally, the success rate in 
extracorporeal shockwave therapy is determined by entry criteria, treatment schemes, the 
lithotriptor used and experience of the physicians [8,12,13]. 
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1. Hepatobiliary and pancreatic disease 
I.I gallbladder stones 
Gallstone disease is an important clinical problem with tremendous economic concequences 
[14,15]. Approximately 10 per cent of the adult population in Western countries have 
gallstones [16,;7]. Only a minority of such patients (10-15 per cent) develop symptoms 
[18,19] and it is generally agreed that only symptomatic gallstones require therapy [19-22]. 
Removal of the gallbladder is the 'gold standard' (because of its curative nature [19,23]), but 
is associated with considerable morbidity and mortality rates: 10-30 and 0.1-0.6 per cent, 
respectively [23-25]. Because of this, much effort has been put into the development of less 
invasive treatment modalities for gallstones. One of these is shockwave therapy. 
The first succesfull shockwave treatment of patients with gallstones was reported in 1986 
[26] and the results of the first large series of patients were published two years later [27]. 
These results were impressive; with minimal complications, 91 per cent of patients were free 
from stones 12-18 months after treatment. The selection criteria initially suggested by the 
Munich group, gradually became less strict [28-45]. Even slightly calcified stones [31,32] 
and largely calcified calculi have been successfully treated [33-35]. Major advantages of 
extracorporeal shockwave therapy are that it can be performed on an outpatient basis, 
requires only intravenous analgesia and is accompanied by minimal morbidity (Table I). To 
date, no associated death has been reported. 
Much experience has been gained now with gallstone lithotripsy [33-45] and more than 
30,000 patients have been treated worldwide [46]. Nevertheless, it has become apparent that 
shockwave therapy will play only a minor part in the management of gallstone disease. Its 
limited role has been determined by two factors: limitations of shockwave treatment itself and 
the introduction of laparoscopic cholecystectomy. 
The limitations of the technique itself are fivefold. First, extracorporeal shockwave 
therapy is applicable to only a minority of patients because only 10-53 per cent meet 
lithotripsy entry criteria [13]. Second, lithotripsy requires adjuvant treatment to dissolve stone 
fragments, such as orally administered bile acids. Third, the good results initially reported 
have not been reproduced and overall results must be considered moderate at best: on 
reviewing the literature Nahrwold found a mean I-year stone clearance rate of 58 per cent 
[47], although reported stone-free rates at 12 months vary considerably (30-78 per cent) as 
shown in Table 1. Fourth, shockwave therapy is inevitably associated with the possibility of 
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stone recurrence, estimated to be approximately 20 per cent at 4 years [48]. Finally, 
lithotripsy is not cost-effective [49-51], except perhaps for elderly patients with a small stone 
load [52]. However, the most important factor determining the limited role of gallstone 
lithotripsy is laparoscopic cholecystectomy. This technique was introduced during the clinical 
evaluation phase of extracorporeal shockwave therapy and was adopted worldwide because 
of its apparent advantages over conventional cholecystectomy [53,54]. As a consequence, 
shockwave treatment is now indicated only for patients of high surgical risk and for those 
who refuse operation. 
At present, patients with a 1-2 cm solitary radiolucent stone in a functional gallbladder 
benefit most from lithotripsy [44,45,55]. It should also be noted that, from a palliative point 
of view, extracorporeal shockwave therapy is very justifiable. It has been convincingly 
demonstrated that lithotripsy of gallstones significantly reduces episodes of biliary pain in 
most patients [52,56] and improves quality of life in general [52,57,58], independent from 
total stone clearance. 
1.2 common bile duct stones 
Stones in the CBD may present as the first sign of gallstone disease, or after 
cholecystectomy, with or without CBD exploration. Surgical bile duct exploration is an 
accepted treatment, but carries a considerable mortality rate that may be as 8 per cent in 
elderly high-risk patients [27,59,60]. In such patients, endoscopic sphincterotomy is the 
treatment of choice [61-63]. 
In about 10 per cent of patients it is not possible to remove stones from the CBD 
endoscopically [61,64,65], because of a discrepancy between the diameter of the stone and 
the bile duct, the presence of duodenal diverticula or previous abdominal surgery, such as 
that involving a Roux-en-Y reconstruction. In such cases extracorporeal shockwave therapy 
may offer an attractive alternative to surgery. The first successful shockwave treatment of 
CBD stones was performed in 1986 [26] and the first large series of patients treated so 
treated was published in 1989 [65]. Successful treatment of intrahepatic stones is also feasible 
[66-69]. 
Much experience with lithotripsy of CBD stones, has been gained to date [49,65-80]. 
Fragmentation is achieved in the majority of cases and stone clearance rates of up to 88 per 
cent have been reported (Table I). Although some authors perform shockwave therapy of 
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CBD stones under ultrasonographic guidance [68.74.77,81]. most consider access to the bile 
duct an imperative prerequisite [82]. Such access, achieved either endoscopically or 
percutaneously, provides both an entrance for fluoroscopic contrast agent and facilitates 
fragment clearance after lithotripsy, preventing iatrogenically induced pancreatitis or 
cholangitis. Additional measures, such as lavage and/or endoscopic or percutaneous 
extraction are necessary in 50-75 per cent of patients [49,65,67,69,71.72,78,82]. 
A major advantage of extracorporeal shockwave therapy of CBD stones is that morbidity 
rates are low (Table 1). Most minor complications, such as hematuria and hemobilia resolve 
within a few days [65,71,76] and serious complications, such as cholangitis, may often be 
regarded as an exacerbation of a pre-existing infection [65,67,71]. The reported mortality 
rate related to shockwave treatment is 0.5 per cent, which is surprisingly low considering the 
complexity of the problem and the population requiring treatment [72]. The mortality rate 
of adjuvant endoscopic or percutaneous procedures, which is about 1 per cent [61.64], must 
also be borne in mind [80]. For CBD stones ihat cannot be removed endoscopically, some 
authors feel that ESWT should be considered before surgery is undertaken, especially in the 
high-risk patient [76,80]. 
1.3 pancreatic duct SlOnes 
Chronic pancreatitis is often associated with calcification within the duct. Such stones may 
cause obstruction and the subsequent increased outflow pressure in the pancreatic duct is one 
pathogenic factor of persistent pain characterizing chronic pancreatitis [83]. When stones are 
present in the main pancreatic duct, sphincterotomy of the duct orifice followed by 
endoscopic stone extraction is the therapy of choice [84,85]. However, this is sometimes 
impossible and more troublesome than endoscopic extraction of CBD stones [85]. Extensive 
surgical procedures, such as side-to-side pancreatojejunostomy and left or main pancreatic 
resection, are often regarded as the only solution [86-88]. Unfortunately, these surgerical 
procedures are associated by a considerable morbidity and mortality rates of 20-40 and 2-5 
per cent, respectively [89,90]. Shockwave treatment therefore seems an attractive alternative 
for the management of pancreatic duct stones that cannot be removed by endoscopic 
extraction. 
The first report of successful extracorporeal shockwave therapy in a patient with chronic 
pancreatitis was published in 1987 [91]. Although pancreatic calculi are usually calcified, 
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non-calcified stones in the panceatic duct can also be treated by lithotripsy [92]. Apart from 
report on shockwave therapy in a large series of 123 patients [93]. experience has usually 
been limited to fewer than 25 patients [83,92,94-98]. Fragmentation and stone clearance rates 
are good; all complications are clinically insignificant [99] (Table 1) . 
Pain relief directly after treatment is observed in nearly all patients, but successful long-
lasting pain relief occurs in 38 to 88 per cent of patients [83,92,94-98]. No associated death 
has been reported to date. Whether long-lasting pain relief can be achieved in these patients 
remains doubtful. In large series of patients operated on for chronic calcifying pancreatitis. 
long-lasting pain relief could not be achieved in 20-40 per cent [88-90,99-101]. Considering 
the moderate results of surgery and its attendant high morbidity and mortality rates, it is our 
opinion that lithotripsy should be the procedure of choice for treating pancreatic duct stones 
that cannot be removed endoscopically [92]. 
2. Salivary gland disease 
Sialolithiasis is both a cause and consequence of chronic sialadenitis. In addition, salivary 
stones may produce acute suppurative sialadenitis. Parotidectomy is an accepted therapy for 
salivary gland stones, but it requires several hours of general anaesthesia and is associated 
with the risk offacial nerve palsy and Frey's syndrome. Removal of the submandibular gland 
may cause lesions of the lingual and hypoglossal nerves, and marginalis branch of the facial 
nerve. 
Extracorporeal shockwave therapy for stones of the large salivary glands has been studied 
almost exclusively in Germany [102·106]. After initial in vitro studies [102], Iro and 
collegues treated the first patient in 1989 [!O3]. The results of a relatively large series of 
patients (n=51) appeared only recently [106]. Sixteen patients had stones in the parotid gland 
and 35 in the submandibular gland; fragmentation was achieved in 88 per cent. At 9-months 
follow-up total clearance of stone fragments was found in 53 per cent and 90 per cent of all 
patients were free from symptoms. Stone clearance was markedly more successful in the 
parotid gland than in the submandibular gland (81 vs. 40 per cent), probably because of 
anatomical and physiological differences between the two. Relief of symptoms was more 
pronounced after treatment of the parotid gland than of the submandibular gland (100 vs. 85 
per cent) because of the difference in stone clearance rates. Most patients (71 per cent) 
required only one session of lithotripsy and no anaesthesia was required in any case. No 
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adjuvant treatment was required and no serious complications were observed (Table 1). 
Although these data are promising, :nore patients and longer follow-up are warranted to 
determine the role of extracorporeal shockvvave treatment in sialolithiasis. Because 
electromagnetic and electrohydraulic machines have substantially larger shockwave focal 
zones, possibly more likely to cause damage to surrounding tissues, shockwave treatment of 
salivary gland stones is likely to be practically possible only with piezoelectric litr.otriptors 
[106]. 
3. Vascular disease 
Extracorporeal shockwave therapy for vascular diseases has been studied experimentally for 
selective thrombus ablation and pretreatment of heavily calcified arteries. 
Thrombosis of coronary and peripheral arteries is a major clinical problem, accompanied 
by large morbidity and mortality rates. Thrombolytic therapy has shortcomings in both 
eligibility and reperlusion rates. Alternatives are therefore being vigorously investigated. 
Because endovascular acoustic energy ablates thrombi with a wide margin of safety, the use 
of an external acoustic generator has been tested [107]. It was found that a significant 
ablation of thrombus mass could be achieved by shockwave treatment without microscopic 
damage to the arterial segments. Since there are no differences in impedance properties 
between thrombus mass and arterial Wall, it has been suggested that thrombus ablation is 
caused solily by the cavitation effect. No in vivo experiments have been reported to date. 
Atherosclerosis is another major clinical problem, often requiring open surgical or 
endovascular interventions. One serious difficulty in endovascular interventions is heavily 
calcified plaques in the artery; such lesions are the major cause of technical failure and 
complications of this rype of intervention [108]. Occlusions may be treated by percutaneous 
ultrasonic angioplasty [109], but recently it has been postulated that shockwaves may be 
useful in the pretreatment of calcified arteries before balloon dilatation and atherectomy 
[110]. Early experimental results of this application of shockwaves are contradictory 
[110, Ill]. A research group in our hospital has demonstrated macroscopic and radiological 
decalcification using an electromagnetic shockwave generator on ex vivo segments of 
calcified abdominal aorta [110]. No perforations were observed nor was there histological 
evidence of significant damage to the non-calcified parts of the vessel. Contrary to these 
results, Cooke and Palfrey could not demonstrate any radiological effect in ex vivo calcified 
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vessels using a spark-gap lithotriptor [111]. No in vivo experimental results have been 
publised to date. 
In summary, extracorporeal shockwave therapy for vascular disease remains experimental 
and its clinical use in the near future remains uncertain. One potentially serious difficulty is 
possible embolization in vivo caused by fragments of thrombi and calcified plaques. 
4. Trauma 
The treatment of fracture non-union is difficult and usually requires multiple surgical 
interventions. Extracorporea..l shockwave therapy may become a non-invasive alternative 
treatment for these healing disturbances [112,113]. Shockwaves are known to be able to 
microfracture orthopaedic cement, resulting in a disruption of the cement-surface interface 
during the revision of total hip arthroplasty [114,115]. Shockwave therapy can also cause 
major gross cortical changes and even bone fracture in a dose-related manner [116]. Applied 
to fractured bone, shockwave treatment has shown a significant enhancement in radiological 
fracture healing and mechanical stability in a controlled experiment in rats [112]. In another 
experiment, dogs treated by shockwave therapy formed radiographically and histologically 
proven bony unions, while untreated dogs had persistent non-unions [117]. It was assumed 
that the stimulating influence of shockwaves on the healing processes of damaged tissues 
results from differences in shockwave susceptibility of different cell types [118]. Such a 
difference in shockwave susceptibility may lead to better growth by less shockwave-sensitive 
cells. These data suggest that extracorporeal shockwave therapy may have a role to play in 
the non-operative treatment of bone healing disturbances, such as pseudoarthrosis, delayed 
union and established non-union of fractures. Further studies are needed to define the full 
potential of this so-called osteotripsy. The first patients with bone healing disturbances are 
currently being treated [112,117]. 
S. Oncology 
Because of the destructive effects of shockwaves on cells, extracorporeal shockwave therapy 
has also been studied in oncology, both as a sole treatment and as pretreatment before 
cytotoxic medication. Since there is no difference in viability after shockwave application 
between normal cells and tumour cells [119], the potential role for shockwave treatment as 
a non-ivasive antineoplastic technique must lie purely in its local1y destructive effects. Russo 
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and co-workers were the first to report an inhibitory effect of shockwaves on the clonogenic 
potential of tumour cells in vitro and tumour growth in vivo [120-123]. A cytocidal and 
cytostatic effect was confirmed by several other authors using different shockwave generators 
on various tumour cell lines [124-130]. The potential ability of shockwave therapy to 
suppress tumour cell growth is, however, temporary [128]. 
The mechanism of action is not yet clear [131,132]. Most probably there is a direct 
mechanical effect on cell membrane structures [124,126], but is an oversimplification to 
consider the cytotoxic effect of shockwave treatment as purely mechanical [133]. Morgan et 
al. and Miller postulated that the destructive effect is enhanced by secondary processes 
[133,134]. The formation of free radicals caused by microcavitation might play an important 
role, but this has not yet been proved experimentally [133]. Further study is needed to 
characterize the lesion at the cellular level [124]. 
Although the majority of cells are killed by acoustic shockwaves over a range of 
frequencies, proliferation of the cells that remaine alive is not adversely influenced [135]. 
This observation is in agreement with reports that extracorporea1 shockwave therapy reduces 
the size of tumours in vivo but does not alter the growth rate [128]. Such findings have led 
to the concept of combining shockwave treatment with cytotoxic drugs in the hope that the 
former will reduce the bulk of the tumour while the latter destroys residual tumour cells. 
Several studies have shown synergistic effects using such a combination [128,130,136-138]. 
The hypothesized mechanism of action of this synergetic effect is an increased membrane 
permeability after shockwave treatment [124]. 
Although the initial results of shockwave therapy in the treatment of tumours are 
encouraging, cautious interpretation is necessary [132,139]. A major drawback is that in vivo 
antitumour effects are less pronounced than those observed in vitro [128,130,136,137,139]. 
Some authors have suggested that the in vitro effects may have been influenced by 
experimental factors [132,134,135,139]. In fact, one cannot exclude that the cytotoxic effects 
observed in vitro might have been experimental artefacts. 
In the oncological context, focused extracorporea1 pyrotherapy must also be mentioned. 
Here, ultrashort focused waves are generated with the specific aim of destroying tumours by 
extracorporea1 application. Although the pressure profiles of the ultrasonic waves differ from 
that of shockwaves, the generation of the former and their transmission through a water bag, 
closely resemble those ofextracorporea1 shockwave therapy. The lesion produced, however, 
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is different. In focused extracorporeal pyrotherapy, the waves cause a very brief period of 
great heat at the focal area. This ultrasonically induced tissue heating together with transient 
cavitation are the main cause of a direct coagulative necrosis [140]. These phenomena 
eventually lead to a decreased tumour growth rate, which has been observed in cultured 
tumour cells and implanted tumours in a variety of animals [141-144]. There seems to be no 
metastatic risk and skin bums are the only obvious side-effects of pyrotherapy [145]. Just as 
for shockwave treatment, pyrotherapy has also been tested as an adjuvant treatment with 
chemotherapy; a synergystic effect is suggested [146,147]. Focused extracorporeal 
pyrotherapy has already been investigated in humans with prostatic, kidney and bladder 
tumours and in benign disorders such as prostatic hyperplasia [145]. 
Most experiments in oncology suggest a potential value for extracorporeal shockwave 
treatment and focused extracorporeal pyrotherapy as non-invasive therapeutic tools for the 
destruction of malignant tumours in vivo. In contrast to radiotherapy, shockwave treatment 
and pyrotherapy have the advantage that waves can be brought to a sharp focus, causing 
fewer side-effects to exposed adjacent normal tissue [135]. Investigations into the possible 
use of extracorporeal shockwave treatment and focused extracorporeal pyrotherapy in 
conjunction with chemotherapy, radiotherapy and immunotherapy seem worthwile. 
Conclusions 
Extracorporeal shockwave therapy is mainly used in the treatment of stones, but other 
applications are being intensively investigated. In urology, shockwave therapy has 
revolutionized the treatment of kidney .and urinary tract stones. Compared with lithotripsy 
of urological calculi, shockwave therapy of stones in other areas has not achieved the same 
high clearance rate, even after adjuvant treatment. Moreover, multiple treatment sessions are 
usually required. Most clinical experience of lithotripsy in general surgery has been gained 
in the field of hepatobiliary and pancreatic interventions. A major advantage of lithotripsy 
is that it can be performed under simple analgesic sedation; most treatments do not require 
anaesthesia at all. The method can therefore be offered to elderly and high-risk patients. 
Extracorporeal shockwave therapy may also be offered as an option to those who refuse 
surgery. 
Since the successful introduction of laparoscopic cholecystectomy the role of shock wave 
treatment of gallbladder stones has been limited [148]. Lithotripsy for stones in the pancreatic 
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duct or CBD is an attractive alternative to surgery when they cannot be removed 
endoscopically. Considering the morbidity and mortality rates associated with surgery, it has 
been suggested that lithotripsy should be tried before operation is undertaken. While we agree 
that this strategy may be suitable for elderly and high-risk patients, it has not been studied 
in randomized controlled trials. 
The initial results of lithotripsy for salivary stones are promising, but the number of 
patients treated is too limited to draw any firm conclusions on its future role. It is also 
premature to predict the role of extracorporeal shockwave therapy in vascular disease and 
oncology; no patients have been treated to date. Studies on shockwave treatment for selective 
thrombus ablation and pretreatment of heavily calcified arteries, however, are certainly 
interesting. The influence of shockwave treatment and pyrotherapy on the viabilty of 
malignant cells and growth rates of tumours also warrant further investigations. Finally, the 
initial results of extracorporeal shockwave therapy in the non-operative treatment of bone 
healing disturbances are encouraging and the first reports of clinical results are eagerly being 
awaited. 
In summary, extracorporeal shockwave therapy has the potential to be an alternative to 
several surgical procedures. It must be stressed, however, that all such applications remain 
experimental. Shockwave therapy in vascular disease, trauma and oncology has almost 
exclusively been studied in an experimental setting. Lithotripsy for stones in the CBD and 
pancreatic duct has not yet been studied in randomized trials, and experience with shockwave 
treatment of salivary gland calculi is still very limited. Even extracorporeal shockwave 
therapy for gallstones may be regarded as still experimental; the American Food and Drug 
Administration has not yet approved lithotriptors for the treatment of gallstones to date [47], 
although already over 30,000 patients have already been treated worldwide [46]. 
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Table 1 : results of lithotripsy of different stones 
Fragmentation 
rates (%) 
Stone clearance 
rates (%) 
Side effects 
(%) 
References 
CBD = common bile duct 
Gallbladder 
stones 
95-100 
30-78 
-colics 
(14-54) 
-cholecystitis 
(1-4) 
-biliary obstruction/ 
pancreatitis 
(0-4) 
13, 26-32, 35-45, 
47, 51 
CBD 
stones 
81-97 
70-88' 
-hematuria 
(2-11 ) 
-hemobilia 
(2-8) 
-septic fever 
(3-6) 
26, 46, 65-67, 
69-73, 75, 76, 
78-81 
Pancreatic 
duct stones 
75-100 
38-100 
-exacerbation 
pancreatitis 
(8-13) 
83, 92-94, 
96-99 
Salivary 
gland stones 
88 
53 
-skin 
petechia 
(14) 
-transient 
gland 
swelling 
(3) 
106 
t) Ponchon [74] and Ihse [731 reported framentalion rates of 53 and 67%, respectively.; since their protocols differred strikingly from most other reports, their data were 
excluded. 
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CHAPTER 12 
Summary and discussion 
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The objective of this study was to determine the role of extracorporeal shock wave lithotripsy 
(ESWL) in the spectrum of treatment modalities for symptomatic gallstones in terms of in 
tenns of eligibilty, stone clearance, safety, symptom relief, general well being and cost-
effectiveness. The factors influencing the public's interest in the study were also studied. 
Laparoscopic cholecystectomy was incorporated in the study, because of its universal 
adoption as the new gold standard for symptomatic gallstones. Finally, the potential value 
of extracorporeal shock waves in fields other than gallbladder stones was investigated. 
Chapter 2 reviews the literature on the currently available treatment modalities for 
symptomatic gallstones. In historical order, open cholecystectomy, oral bile acid therapy. 
contact dissolution, ESWL, cholecystolithotomy, rotary contact lithotripsy and laparoscopic 
cholecystectomy are discussed in detail. Cholecystectomy is the most rational treatment for 
symptomatic gallstones. First, because cholecystectomy is applicable in most patients, and 
second, because there is no possibility of stone recurrence. The limited role of nonoperative 
alternatives seems determined by their limited applicability, their limited efficacy, the 
necessity for a more extended diagnostic work-up and stone recurrence. Laparoscopic 
cholecystectomy will be the new gold standard for symptomatic gallstones. Alternative 
treatment modalities may be reserved for patients with a high surgical risk and for patients, 
who refuse surgery. 
Chapter 3 reports on our calculations on the eligibility for ESWL using different entry 
criteria. It was found that only a small part of the symptomatic gallstone patients is eligible 
for ESWL: 13.4-46.9%, depending on the entry criteria used. Ideal patients (with a solitary 
non-calcified gallstone of S;20mm) were found in only 10.3%. When the overall results of 
ESWL were compared with eligibility, there was no inverse relationship. This suggests that 
patient selection is not the only important factor determining the results of therapy. Other 
factors, such as treatment schemes, the lithotriptors used and experience of the treating 
physicians, may also play an important role in the outcome of ESWL therapy. 
Chapter 4 presents our results of gallstone lithotripsy in 133 patients. At I year after the 
first ESWL-session, 51.0% of the patients with a solitary stone and 8.3 % of the patients with 
2-10 stones were free of concrements. Major complications comprised pancreatitis (3.0%) 
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and acute cholecystitis (0.8%). At final follow-up (mean: 17.7 months), 27.8% of the 
patients were free of stones and 22.6% underwent cholecystectomy. Fourteen per cent of the 
patients developed recurrent stones. Our results reconfirmed that ESWL is relatively safe and 
moderately effective in selected patients. Considering the poor results in multiple stones, 
ESWL should be confined to solitary stones. 
Chapter 5 describes the course of biliary and gastrointestinal symptoms in 23 patients 
randomized to ESWL and 26 patients randomized to conventional cholecystectomy. Biliary 
colics were cured in 90.9 % and 45.4 % of the patients within 3 months after cholecystectomy 
or ESWL, respectively. Stomach swelling and fatty food upset responded to cholecystectomy. 
while nausea reponded to ESWL. Vomiting, pyrosis, ructus, diarrhea and constipation did 
not respond to gallstone therapy. Cholecystectomy is, therefore, superior to ESWL in 
improving biliary and gastrointestinal complaints. However, in patients who are unfit or 
unwilling to undergo surgery, ESWL is a relatively adequate therapy because the majority 
of patients tend to benefit from it in terms of symptom relief. 
Chapter 6 deals with the course of quality of life after ESWL in comparison with open 
cholecystectomy in the same patient group as described in Chapter 5. Both treatment 
modalities were found to improve quality of life. Open cholecystectomy, however, improved 
quality of life significantly better than ESWL during the course of one year. Open 
cholecystectomy is, therefore, superior to ESWL in improving quality of life and remains the 
therapy of choice for symptomatic gallstones. However, in patients who are unfit or 
unwilling to undergo surgery, ESWL is an adequate form of treatment because the majority 
of patients tend to benefit from it in terms of quality of life. 
Chapter 7 focuses on cost-effectiveness of ESWL in comparison with cholecystectomy. The 
results of our own cost-effectiveness analysis as well as the data in the literature indicate that 
ESWL is not as cost-effective as cholecystectomy. Cholecystectomy is, therefore, from an 
economic point of view, preferable to ESWL, except perhaps for elderly patients with 
solitary stones. 
Chapter 8 reports on the findings at oral cholecystography (OCG) and its implications for 
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nonsurgical therapy of symptomatic gallstones. Age was found to be a determinant for 
calcification of gallstones. Elderly patients, in whom nonsurgical treatment of gallbladder 
stones is most likely to be indicated, are, therefore, less likely to be suitable for nonsurgical 
gallstone therapy. 
Chapter 9 analyses patient accrual into our randomized study comparing ESWL with open 
cholecystectomy. It was found that in a 3-years intake period, only 8.3 % of the analyzed 
patients could be entered into the trial. Three factors were identified hampering patient 
accrual. First, restricted eligibility for ESWL (and thus for the study), which could not have 
been predicted on the data provided in the literature. Second, the introduction of laparoscopic 
cholecystectomy. And third, strong patient's preference for a certain treatment modality for 
gallstone disease, inhibiting randomization. It is concluded that it is not always feasible to 
conduct a randomized study in surgery satisfactory due to unforseen circumstances. Because 
the management of gallstone disease is quickly evolving and because the characteristics of 
the different treatment modalities are so very divergent, a good randomized controlled study 
of laparoscopic cholecystectomy can most probably never be performed. 
Chapter 10 investigates quality of life and the course of biliary and gastrointestinal 
symptoms afer laparoscopic cholecystectomy and conventional cholecystectomy. Quality of 
life significantly improved 6 months after laparoscopic cholecystectomy and to a similar 
degree 12 months after conventional cholecystectomy. Stomach swelling, fatty food upset and 
nausea improved significantly after cholecystectomy but sooner after laparoscopic than after 
conventional cholecystectomy. Vomiting and belching had a tendency to improve slightly, 
while pyrosis, constipation and diarrhea did not improve. Biliary pain was cured in 81 % of 
the patients directly after cholecystectomy and not reported after 6 months after treatment. 
It is concluded that cholecystectomy improves quality of life and cures nausea, fatty food 
upset, stomach swelling and biliary pain. Furthermore, laparoscopic cholecystectomy 
improves quality of life and symptomatology to the same degree in an earlier stage than 
conventional cholecystectomy. Therefore, laparoscopic cholecystectomy may be preferable 
to conventional cholecystectomy for the treatment of uncomplicated symptomatic gallstones. 
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Chapter 11 discusses the potential applications of extracorporeal shock waves in surgery. 
Lithotripsy of stones in the gallbladder, common bile duct, pancreatic duct and salivary gland 
ducts are described. Steps towards the management of bone healing disturbances, the 
inhibition of tumor growth, selective thrombus ablation and pretreatment of heavily calcified 
arteries are discussed. Results indicate that for selected patients, extracorporeal shock wave 
therapy may serve as a useful addition to the surgical armamentarium. 
Much research is being performed on the various aspects of the different treatment modalities 
for symptomatic gallstone disease. This research is in full development and major advances 
have been made. Therefore, it is somewhat disturbing that laparoscopic cholecystectomy 
could have emerged as the new standard therapy for symptomatic gallstones despite that a 
solid scientific basis for this unanimous acceptance, in fact, fails. 
We studied ESWL to determine its role in the whole spectrum of treatment modalities for 
symptomatic gallstones. We found that ESWL may not be regarded as the therapy of choice 
for symptomatic gallstones. It is only applicable in a minority of patients and the efficacy is 
relatively poor, especially when multiple stones are treated. As compared to cholecystectomy, 
ESWL is not as effective in improving biliary pain, gastrointestinal symptoms and quality of 
life. Finally, ESWL is accompanied by stone recurrence and considerable costs. 
Although ESWL did not come up to the high expectations, ESWL may still playa role for 
it is relatively safe and tends to improve quality of life and biliary pain. ESWL is especially 
indicated in elderly, high-risk patients. Considering that patient's preference is becoming 
increasingly important there should also be place for gallstone lithotripsy for patients who 
refuse surgery. For the latter group, it might be argued that only solitary stones should be 
treated. The results of other applications of extracorporeal shock waves in surgery are 
promising. 
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SAMENV ATTING EN DISCUSSIE 
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Het primaire doel van de in dit proefschrift beschreven studie was te onderzoeken welke rol 
galsteenvergruizing ZOll kunoen spelen in het arsenaal van galsteentherapieen. Het onderzoek 
richtte zich in het bijzonder op de intrinsieke eigenschappen van ESWL, zoals 
toepasbaarheid, steenklaring, veiligheid, de invloed op biliaire- en gastrointestinale 
symptomen, de invloed op het algemeen welbevinden van de patient en kosten-effectiviteit. 
Factoren die de interesse van het publiek in de studie bejnvloeden werden ook bestudeerd. 
De laparoscopische cholecystectomie werd in de studie opgenomen vanwege het feit dat deze 
ingreep inmiddels wereldwijd wordt gezien als de voorkeursbehandeling voor symptomatische 
galstenen. Tenslotte werden de mogelijke andere toepassingen van schokgolven bestudeerd. 
Hoofdstuk 2 geeft eeo algemeen overzicht van de thans beschikbare therapievormen voor 
symptomatische galstenen. In historische volgorde worden achtereenvolgens behandeld de 
open (inmiddels 'ldassieke') cholecystectomie, galzuur-therapie, contact-dissolutie, 
schokgolfvergruizing, cholecystolithotomie, 'rotary contact lithotripsy' en laparoscopische 
cholecystectomie. Extirpatie van de galblaas is de meest rationele behandeling voor 
symptomatische galstenen. Allereerst, is cholecystectomie toepasbaar in vrijwel aile patienten 
en ten tweede is er na verwijdering van de galblaas geen kans op recidief-steenvorming. De 
rol van niet-operatieve behandelmethoden lijkt beperkt. Dit wordt veroorzaakt doordat niet-
operatieve behandelvormen gepaard gaan met een beperkte toepasbaarheid, een beperkte 
effectiviteit, de noodzaak voor eeo meer uitgebreide diagnostische screening en de kans op 
recidief-steenvorming. Op basis van de beschikbare literatuur kan worden geconcludeerd dat 
de laparoscopische cholecystectomie de nieuwe gouden standaard is voor symptomatische 
galstenen. Niet-operatieve behandelmethoden zuHen gereserveerd zijn voor patienten met een 
hoog operatie-risico of patienten, die geen operatieve ingreep wensen te ondergaan. 
Hoofdstuk 3 geeft de toepasbaarheid van ESWL weer, zoals die werd berekend voor de 
verschillende insluitcriteria. Slechts de minderheid van de patienten blijkt voor vergruizing 
van hun galstenen in aanmerking te kO\llen: 13.4-46.9% afhankelijk van de gehanteerde 
insluitcriteria. Slechts 10.3% van de patienten kunnen als 'ideale' vergruizingskandidaten 
worden bestempeld. 'Ideaal' wil in deze context zeggen maximaal een niet-gecalcificeerde 
steen met een maximale diameter van maximaal 20mm. Wanneer de resultaten van ESWL 
worden afgezet tegen de berekende toepasbaarheid, blijkt er geen omgekeerde relatie te 
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bestaan. Dit suggereert dat selectie van patienten nlet de enige belangrijke factor kan zijn die 
de resultaten van de behandeling bepaalt. Andere factoren, zoals behandelprotocollen, de 
soort vergruizer en de ervaring van de behandelaar moeten een belangrijke rol spelen in het 
uiteindelijke resultaat van de vergruizing. 
In Hoofdstuk 4 worden de Rotterdamse resultaten gepresenteerd van de verguizingen bij 133 
galsteenpatienten. Na 1 jaar blijken respectievelijk 51.0% van de patienten met een solitaire 
steen en 8.3% van de patienten met 2~10 stenen vrij van concrementen te zijn. Ernstige 
complicaties bestaan uit pancreatitis (3.0%) en acute cholecystitis (0.8%). Tijdens de laatste 
follow-up met een gemiddeld duur van 17.7 maanden, is 27.8% van de patienten steenvrij 
en 22.6% heeft alsnog cholecystectomie ondergaan. Veertien procent van de patienten 
ontwikkelt recidief-galstenen. Deze resultaten bevestigen dat ESWL veilig is en relatief 
effectief voor geselecteerd patienten. Gezien de magere resulaten bij multipele stenen, dient 
ESWL slechts te worden toegepast bij patienten met solitaire stenen. 
Hoofdstuk 5 beschrijft het verloop van biliaire en gastrointestinale klachten bij 23 patienten 
gerandomiseerd voor ESWL en 26 patienten gerandomiseerd voor klassieke cholecystectomie. 
Binnen drie maanden na de behandeling genezen kolieken bij 90.9 % van de cholecystectomie-
patienten en 45.4% van de ESWL-patienten. Opgeblazen gevoel en vet-intolerantie reageren 
op cholecystectomie, terwijl misselijkheid afneemt na ESWL. Braken, zuurbranden, 
opboeren, diarree en obstipatie reageren niet op galsteenbehandeling. Cholecystectomie is 
derhalve superieur aan ESWL voor de behandeling van kolieken en gastrointestinale klachten. 
Echter voor patienten met een hoog operatie-risico en patienten die operatie afwijzen, kan 
ESWL een relatief adequate therapie zijn, omdat biliare en gastrointestinale als regel klachten 
afnemen. 
In Hoofdstuk 6 wordt de invloed van therapie op het verloop van het algemeen welbevinden 
van galsteenpatienten behandeld. Dit algemeen welbevinden of 'kwaliteit van leven' werd 
bepaald in dezelfde patientengroepen als beschreven in Hoofdstuk 5. Zowel ESWL als 
cholecystectomie verbeteren het algemeen welbevinden van galsteenpatienten. Echter de 
klassieke cholecystectomie verbeten de kwaliteit van leven significant beter. 
Cholecystectomie is daarom superieur aan ESWL en moet als gouden standaard beschouwd 
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blijven voor de behandeling van symptomatische galstenen. Voor patienten met een hoog 
operatie-risico en patienten die operatie afwijzen moet ESWL gezien worden als een adequate 
behandelvorm daar het het algemeen welbevinden duidelijk verbetert. 
In Hoofdstuk 7 wordt ingegaan op de kosten-effectiviteit van ESWL in vergelijking met die 
van cholecystectomie. Zowel onze eigen analyse als de literatuurgegevens gegeven aan dat 
ESWL niet zo kosten-effectief is als cholecystectomie. Vanuit economisch oogpunt is 
cholecystectomie derhalve te preferen boven ESWL. Een uitzondering hierop vormen wellicht 
oudere patienten met solitaire stenen. 
Hoofdstuk 8 geeft een analyse van de bevindingen bij de orale cholecystografieen van 448 
symptomatische galsteenpatienten en de implicaties hiervan voor niet-operatieve 
behandelvormen van galstenen. Leeftijd blijkt te predisponeren voor het hebben van verkalkte 
galstenen. Oudere patienten komen daarom minder in aanmerking voor niet-operatieve 
behandelvormen van galstenen. 
Hoofdstuk 9 analyseert de instroom van patienten in het gerandomiseerde gedeelte van de 
ROGAL-studie. In een intake-periode van drie jaar konden slechts 8.3 % van de 
geanalyseerde patienten worden gerandomiseerd. Drie factoren blijken verantwoordelijk te 
zijn geweest voor deze matige patienten-instroom. Allereerst de beperkte toepasbaarheid van 
ESWL. Ben beperking, overigens, die niet kon worden voorspeld op basis van de destijds 
beschikbare literatuurgegevens. Ten tweede de introductie van de laparoscopische 
cholecystectomie. En ten derde de -tijdens de studie wisselende- uitdrukkelijke voorkeur 
voor een bepaalde behandelmethode van de zijde van de patient. Er wordt geconcludeerd dat 
het binnen de chirurgie door onvoorziene omstandigheden niet altijd mogelijk is een 
gerandomiseerde studie naar tevredenheid uit te voeren. Omdat ontwikkelingen binnen het 
gebied van de verschillende behandelvormen zich snel opvolgen en omdat de karakteristieken 
van de diverse behandelvormen zo uiteenlopen, zal een goede gerandomiseerde studie met 
de laparoscopische cholecystectomie waarschijnlijk onuitvoerbaar zijn. 
Hoofdstuk 10 gaat in op het algemeen welbevinden en het verloop van biliaire en 
gastrointestinale klachten na laparoscopische en klassieke cholecystectomie. Zes maanden na 
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laparoseopisehe eholecysteetomie en twaalf maanden na klassieke eholecystectomie verbetert 
de kwaliteit van leven significant. Opgeblazen gevoel, vet-intolerantie en misselijkheid 
reageren op eholecystectomie, maar beduidend sneller op laparoseopisehe dan op klassieke 
cholecystectomie. Braken en opboeren lijken wat te verbeteren, teTh'ijI zuurbranden, 
obstipatie en diarree niet reageren. Biliaire pijn geneest in 81 % van de gevallen aansluitend 
op eholecystectomie en wordt niet meer gerapporteerd na 6 maanden. Er wordt 
geconcludeerd dat eholecystectomie het algemeen welbevinden verbetert en misselijkheid, 
vet-intolerantie, opgeblazen gevoeI en kolieken geneest. Laparoseopisehe eholecystectomie 
verbetert de kwaliteit van leven en diverse biliaire en gastrointestinale klachten sneller dan 
klassieke eholecystectomie. Laparoseopisehe eholecysteetomie is daarom te prefereren. 
Hoofdstuk 11 geeft een overzicht van de mogelijke andere toepassingen van schokgolven 
binnen de chirurgie. Vergruizing van stenen in de galblaas, galwegen, alvleesklier en 
speekselklieren worden besproken. Ook wordt ingegaan op mogelijkheden voor de 
behandeling van stoomissen in de botgenezing, de inhibitie van tumorgroei, selectieve 
thrombusverwijdering en de voorbehandeling van sterk verkalkte bloedvaten. De resultaten 
geven aan dat het gebruik van sehokgolven van waarde is binnen het geheel van ehirurgisehe 
behandelteehnieken. 
Onderzoek naar de verschillende aspecten van de diverse behandelvormen van galstenen mag 
zieh verheugen in een brede belangstelling. Dit onderzoek is nog steeds in volle ontwikkeling 
en belangrijke vooruitgangen zijn geboekt de laatste jaren. Het is daarom verontrustend dat 
de laparoseopisehe eholecystectomie kon verworden tot therapie van voorkeur, terwijl 
hiervoor, in feite, een solide wetensehappelijke basis ontbreekt. 
Wij bestudeerden galsteenvergruizing om tot een plaatsbepaling van deze nieuwe techniek te 
komen binnen het spectrum van behandelmethoden voor symptomatisehe galstenen. We 
vonden dat ESWL niet mag worden besehouwd als de voorkeursbehandeling van 
symptomatisehe galstenen. Galsteenvergruizing is beperkt toepasbaar en de resultaten zijn 
matig, zeker wanneer multipele stenen worden behandeld. Vergeleken met eholecystectomie, 
is ESWL is niet zo effectief ten aanzien van het verbeteren van kolieken, gastrointestinale 
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klachten en het algemeen welbevinden. Tenslotte gaat ESWL gepaard met aanzienlijke kosten 
en recidief-steenvorming. 
Hoewel galsteenvergruizing niet aan de hooggespannen verwachtingen heeft kunnen Yoldoen, 
kan toch gesteld worden clat ESWL relatief veilig is, het algemeen welbevinden verbetert en 
de frequentie van galsteenkolieken doet afnemen. Er is daarom toch een rol voor 
galsteenvergruizing weggelegd en weI speciaal voar oudere patienten met een hoog operatie-
risico. Gezien het feit dat de voorkeuren van patienten steeds een steeds belangrijker rol gaan 
spelen, is er ook een plaats voor ESWL voor patienten die operatie afwijzen. Voor deze 
groep zou kunnen worden gesteld dat zie hiervoor alleen in aanmerking mogen komen 
wanneer zij een solitaire galsteen hebben. De resultaten van andere toepassingen van 
schokgolven binnen de chirurgie zijn hoopgevend. 
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Curriculum vitae 
De auteur van elit proefschrift werd geboren op 23 oktober 1965 in Rotterdam. De 
middelbare school-opleiding CYWO) werd gevolgd aan de Christelijke scholengemeenschap 
Melanchthon te Rotterdam. In september 1984 werd de medische studie begonnen aan de 
Erasmus Universiteit Rotterdam. Na het behalen van het doctoraal examen in juli 1988 werd 
voor de periode van een jaar gewerkt als student-assistent in het Laboratorium Inwenelige 
Geneeskunde ill van het Academisch Ziekenhuis Dijkzigt (supervisie: Prof. Dr G. 
Hennemann). Het artsexamen werd behaald in maar! 1991. In de periode van apri11991 tot 
juli 1993 werd in het kader van de "Rotterdam Gallstone Study-ROGAL" gewerkt aan elit 
proefschrift (supervisie: Prof. Dr O. T. Terpstra en Prof. Dr H.A. Bruining). Van juli tot en 
met december 1993 werd gewerkt als arts-assistent (AGNIO) op de afdeling Algemene 
Heelkunde van het Academisch Ziekenhuis Dijkzigt (hoofd: Prof. Dr J. Jeekel). Op dezelfde 
afdeling werd per 1 januari 1994 de opleiding tot algemeen chirurg aangevangen (opleider: 
Prof. Dr H.A. Bruining). 
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